<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">79830</article-id><article-id pub-id-type="doi">10.7554/eLife.79830</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells, biomarkers, and response to substrate reduction therapy</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-278092"><name><surname>Boddupalli</surname><given-names>Chandra Sekhar</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1406-7973</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-278322"><name><surname>Nair</surname><given-names>Shiny</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4081-7811</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-278309"><name><surname>Belinsky</surname><given-names>Glenn</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-278310"><name><surname>Gans</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-278311"><name><surname>Teeple</surname><given-names>Erin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-278710"><name><surname>Nguyen</surname><given-names>Tri-Hung</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-278313"><name><surname>Mehta</surname><given-names>Sameet</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-278314"><name><surname>Guo</surname><given-names>Lilu</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-278315"><name><surname>Kramer</surname><given-names>Martin L</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-278316"><name><surname>Ruan</surname><given-names>Jiapeng</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-278317"><name><surname>Wang</surname><given-names>Honggge</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" id="author-278318"><name><surname>Davison</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf9"/></contrib><contrib contrib-type="author" id="author-284517"><name><surname>Kumar</surname><given-names>Dinesh</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-278319"><name><surname>Vidyadhara</surname><given-names>DJ</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf10"/></contrib><contrib contrib-type="author" id="author-278320"><name><surname>Zhang</surname><given-names>Bailin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf11"/></contrib><contrib contrib-type="author" id="author-278321"><name><surname>Klinger</surname><given-names>Katherine</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-262226"><name><surname>Mistry</surname><given-names>Pramod K</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3447-6421</contrib-id><email>pramod.mistry@yale.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Internal Medicine, Yale School of Medicine</institution><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/027vj4x92</institution-id><institution>Translational Sciences, Sanofi</institution></institution-wrap><addr-line><named-content content-type="city">Framingham</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Yale Center for Genome Analysis, Yale School of Medicine</institution><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution>Department of Neuroscience, Yale School of Medicine</institution><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution>Department of Molecular &amp; Cellular Physiology, Yale School of Medicine</institution><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>16</day><month>08</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e79830</elocation-id><history><date date-type="received" iso-8601-date="2022-04-28"><day>28</day><month>04</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-07-08"><day>08</day><month>07</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-05-16"><day>16</day><month>05</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.05.13.491834"/></event></pub-history><permissions><copyright-statement>© 2022, Boddupalli, Nair et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Boddupalli, Nair et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-79830-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-79830-figures-v2.pdf"/><related-article related-article-type="commentary" ext-link-type="doi" xlink:href="10.7554/eLife.81890" id="ra1"/><abstract><sec id="abs1"><title>Background:</title><p>Neuronopathic Gaucher disease (nGD) is a rare neurodegenerative disorder caused by biallelic mutations in <italic>GBA</italic> and buildup of glycosphingolipids in lysosomes. Neuronal injury and cell death are prominent pathological features; however, the role of <italic>GBA</italic> in individual cell types and involvement of microglia, blood-derived macrophages, and immune infiltrates in nGD pathophysiology remains enigmatic.</p></sec><sec id="abs2"><title>Methods:</title><p>Here, using single-cell resolution of mouse nGD brains, lipidomics, and newly generated biomarkers, we found induction of neuroinflammation pathways involving microglia, NK cells, astrocytes, and neurons.</p></sec><sec id="abs3"><title>Results:</title><p>Targeted rescue of <italic>Gba</italic> in microglia and neurons, respectively, in <italic>Gba</italic>-deficient, nGD mice reversed the buildup of glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph), concomitant with amelioration of neuroinflammation, reduced serum neurofilament light chain (Nf-L), and improved survival. Serum GlcSph concentration was correlated with serum Nf-L and ApoE in nGD mouse models as well as in GD patients. <italic>Gba</italic> rescue in microglia/macrophage compartment prolonged survival, which was further enhanced upon treatment with brain-permeant inhibitor of glucosylceramide synthase, effects mediated via improved glycosphingolipid homeostasis, and reversal of neuroinflammation involving activation of microglia, brain macrophages, and NK cells.</p></sec><sec id="abs4"><title>Conclusions:</title><p>Together, our study delineates individual cellular effects of <italic>Gba</italic> deficiency in nGD brains, highlighting the central role of neuroinflammation driven by microglia activation. Brain-permeant small-molecule inhibitor of glucosylceramide synthase reduced the accumulation of bioactive glycosphingolipids, concomitant with amelioration of neuroinflammation involving microglia, NK cells, astrocytes, and neurons. Our findings advance nGD disease biology whilst identifying compelling biomarkers of nGD to improve patient management, enrich clinical trials, and illuminate therapeutic targets.</p></sec><sec id="abs5"><title>Funding:</title><p>Research grant from Sanofi; other support includes R01NS110354, Yale Liver Center P30DK034989, pilot project grant.</p></sec></abstract><kwd-group kwd-group-type="author-keywords"><kwd>Gaucher disease</kwd><kwd>neuroinflammation</kwd><kwd>microglia</kwd><kwd>GBA</kwd><kwd>NK cells</kwd><kwd>lipids</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004339</institution-id><institution>Sanofi</institution></institution-wrap></funding-source><award-id>Research grant from Sanofi</award-id><principal-award-recipient><name><surname>Mistry</surname><given-names>Pramod K</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004339</institution-id><institution>Sanofi US</institution></institution-wrap></funding-source><award-id>other support includes R01NS110354</award-id><principal-award-recipient><name><surname>Mistry</surname><given-names>Pramod K</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>In neurodegeneration of Gaucher disease, glucosylceramides trigger neuroinflammation via attrition of homeostatic microglia and transition to lipid-laden damage-associated microglia concurrently with infiltration of diverse immune cells including activated NK cells and CCR2<sup>+</sup> macrophages, ameliorated by substrate reduction therapy.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>In Gaucher disease (GD), biallelic mutations in GBA underlie defective acid β-glucosidase (glucocerebrosidase, GCase) and buildup of the primary substrate, glucosylceramide (GluCer), and its inflammatory metabolite glucosylsphingosine (GlcSph) in the lysosomes (<xref ref-type="bibr" rid="bib25">Grabowski et al., 2021</xref>). GD is classified into three broad phenotypes based on the absence (type 1 GD, GD1) or onset of early-onset neurodegeneration in childhood (fulminant GD type 2, GD2, and slower chronic neurodegeneration, GD3). Adults with GD1 have a markedly increased risk of Parkinson’s disease and Lewy body dementia (PD/LBD) (<xref ref-type="bibr" rid="bib10">Bultron et al., 2010</xref>; <xref ref-type="bibr" rid="bib25">Grabowski et al., 2021</xref>). Moreover, heterozygous carriers of GBA mutations are at an increased risk of PD/LBD (<xref ref-type="bibr" rid="bib4">Aharon-Peretz et al., 2004</xref>; <xref ref-type="bibr" rid="bib55">Sidransky and Lopez, 2012</xref>; <xref ref-type="bibr" rid="bib54">Sidransky et al., 2009</xref>). Notably, low GCase is reported in the brains of sporadic PD patients who do not harbor GBA mutations (<xref ref-type="bibr" rid="bib24">Gegg et al., 2022</xref>). Together, GBA variants and GCase deficiency are important determinants of a wide spectrum of neurodegenerative diseases.</p><p>Glucosylceramide and glucosylsphingosine display potent inflammatory and immunogenic activities (<xref ref-type="bibr" rid="bib42">Nagata et al., 2017</xref>; <xref ref-type="bibr" rid="bib43">Nair et al., 2015</xref>; <xref ref-type="bibr" rid="bib44">Nair et al., 2016</xref>; <xref ref-type="bibr" rid="bib45">Pandey et al., 2017</xref>). Treatment of non-neuronopathic GD1 involves enzyme replacement therapy (ERT) targeted to the macrophages via mannose receptors and substrate reduction therapies (SRTs) using inhibitors of glucosylceramide synthase (GCS) (<xref ref-type="bibr" rid="bib16">Cox et al., 2000</xref>; <xref ref-type="bibr" rid="bib39">Mistry et al., 2017a</xref>; <xref ref-type="bibr" rid="bib40">Mistry et al., 2017b</xref>; <xref ref-type="bibr" rid="bib46">Platt et al., 2018</xref>). However, currently, there are no effective therapies for the devastating neurodegenerative sequela of GBA mutations. In GD1, SRT is predicated on the concept that the rate of synthesis of GluCer is reduced to match residual enzyme activity due to GBA mutations (<xref ref-type="bibr" rid="bib46">Platt et al., 2018</xref>). However, in neurodegenerative GD2 and GD3, residual glucocerebrosidase activity is profoundly depressed due to severe GBA mutations. A randomized-controlled trial of brain-penetrant SRT, N-butyldeoxynojirimycin. in patients’ GD3 was unsuccessful in ameliorating neurological manifestations. However, N-butyldeoxynojirimycin is a relatively weak inhibitor of GCS with significant off-target effects (<xref ref-type="bibr" rid="bib48">Schiffmann et al., 2008</xref>). Using a more specific, brain-penetrant GCS inhibitor in a chemically induced model of nGD, some disease pathways were ameliorated on bulk RNA analysis, but had no effect on inflammatory pathways (<xref ref-type="bibr" rid="bib8">Blumenreich et al., 2021</xref>).</p><p>Microglia are specialized, self-renewing, CNS-resident macrophages that represent the dominant immune cells involved in maintaining CNS homeostasis. Emerging data from single-cell analysis and genome-wide association studies of several neurodegenerative diseases have revealed a central role of microglia in neurodegeneration (<xref ref-type="bibr" rid="bib12">Chen and Colonna, 2021a</xref>). Although several mechanisms have been proposed to explain neurodegeneration associated with GBA mutations, most studies in GD have focused on GBA deficiency in neurons, while contribution of other cell types in driving the disease pathology has been considered minor (<xref ref-type="bibr" rid="bib14">Cho et al., 2019</xref>; <xref ref-type="bibr" rid="bib60">Vitner et al., 2015</xref>). Immunohistochemical evidence of microglial alteration have been reported in neuronopathic GD, but the effect of GBA deficiency in microglia per se is not understood. Further studies are warranted to investigate the immune landscape of nGD to clearly delineate therapeutic targets and generate biomarkers.</p><p>Hitherto, studies aimed at understanding the mechanisms of neuroinflammation in neurodegeneration due to GBA deficiency have solely relied on bulk cell population analysis, which have hindered the delineation of heterogeneity and complexity of the immune milieu within the brain as well as the role of GBA in individual cell types of the brain. Here, we applied an integrated approach based on novel mouse models, lipidomic analyses, scRNA-seq of immune cells, and brain snRNA-seq to decipher temporospatial components of neuroinflammation associated with <italic>GBA,</italic> deficiency including immune cell subsets, activated pathways, as well as probe therapeutic targets and discover novel biomarkers. Importantly, we used both early-onset neuronopathic GD mice <italic>Gba</italic><sup>lsl/lsl</sup> (loxP-stop-loxP) mice, with a germline deletion of <italic>Gba</italic> (henceforth referred to as nGD mice) which phenocopies human GD2, fulminant neuronopathic GD (<xref ref-type="bibr" rid="bib20">Enquist et al., 2007</xref>) as well as a new mouse model of microglia-specific <italic>Gba</italic> deletion in <italic>Gba<sup>fl/fl</sup></italic> mice that mimics the late-onset progression seen in some patients with GD1. To further understand the function of <italic>Gba</italic> in microglial and neuronal homeostasis and disease progression, we developed additional new nGD mouse models with microglia and neuron-specific rescue of <italic>Gba</italic>.</p><p>We evaluated brain-penetrant inhibitor of GCS as a therapeutic strategy in both early- and late-onset nGD models to assess its impact on reducing cellular glycosphingolipids, individual components of neuroinflammation and neurodegeneration while elucidating temporospatial cellular events. Our findings define a previously unreported role of glycosphingolipid-laden microglia and macrophages along with NK cells and astrocytes in neurodegeneration associated with <italic>Gba</italic> deficiency while also revealing novel biomarkers and therapeutic targets.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD11b</td><td align="left" valign="bottom">BD Biosciences</td><td align="char" char="." valign="bottom">583,553</td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD11b</td><td align="left" valign="bottom">BD Biosciences</td><td align="char" char="." valign="bottom">552,850</td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">ACSA-2</td><td align="left" valign="bottom">Miltenyi Biotech</td><td align="char" char="hyphen" valign="bottom">130-123-284</td><td align="char" char="." valign="bottom">(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD45</td><td align="left" valign="bottom">Biolegend</td><td align="char" char="." valign="bottom">103,133</td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">NK1.1</td><td align="left" valign="bottom">BD Biosciences</td><td align="char" char="." valign="bottom">562,864</td><td align="char" char="." valign="bottom">(1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CCR2</td><td align="left" valign="bottom">R and D</td><td align="left" valign="bottom">FAB5538F</td><td align="char" char="." valign="bottom">(1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD3</td><td align="left" valign="bottom">Biolegend</td><td align="char" char="." valign="bottom">100,241</td><td align="char" char="." valign="bottom">(1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">NK1.1</td><td align="left" valign="bottom">Biolegend</td><td align="char" char="." valign="bottom">108,753</td><td align="char" char="." valign="bottom">(1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="char" char="." valign="bottom">1 A/1-E</td><td align="left" valign="bottom">Biolegend</td><td align="char" char="." valign="bottom">107,639</td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD4</td><td align="left" valign="bottom">BD Biosciences</td><td align="char" char="." valign="bottom">563,790</td><td align="char" char="." valign="bottom">(1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD4</td><td align="left" valign="bottom">BD Biosciences</td><td align="char" char="." valign="bottom">558,107</td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Gr-1</td><td align="left" valign="bottom">Biolegend</td><td align="char" char="." valign="bottom">108,440</td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Ly-6C</td><td align="left" valign="bottom">Invitrogen</td><td align="char" char="hyphen" valign="bottom">47-5932-82</td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD64</td><td align="left" valign="bottom">Biolegend</td><td align="char" char="." valign="bottom">139,306</td><td align="char" char="." valign="bottom">(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">B220</td><td align="left" valign="bottom">eBioscience</td><td align="char" char="hyphen" valign="bottom">47-0452-80</td><td align="char" char="." valign="bottom">(1:200)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">CD8a</td><td align="left" valign="bottom">eBioscience</td><td align="char" char="hyphen" valign="bottom">56-0081-82</td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IL-1Beta</td><td align="left" valign="bottom">Invitrogen</td><td align="char" char="hyphen" valign="bottom">17-7114-80</td><td align="char" char="." valign="bottom">(1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IFNγ</td><td align="left" valign="bottom">Biolegend</td><td align="char" char="." valign="bottom">505,808</td><td align="char" char="." valign="bottom">(1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IFNγ</td><td align="left" valign="bottom">BD Biosciences</td><td align="char" char="." valign="bottom">562,020</td><td align="char" char="." valign="bottom">(1:250)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Brdu Flow kit</td><td align="left" valign="bottom">BD Pharmingen</td><td align="char" char="hyphen" valign="bottom">51-9000019AK</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">5-Bromo-2'-deoxyuridine</td><td align="left" valign="bottom">Cayam Chemical Company</td><td align="char" char="." valign="bottom">15,580</td><td align="left" valign="bottom">180 µg/ml (injected) and 800 µg/ml (in water)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">Cell Rox Deep Red kit</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">C10422</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s2-1"><title>Patients</title><p>Stored serum samples of GD patients were analyzed. All patients had diagnosis of GD based on &lt;10% of normal leucocyte acid-β glucosidase activity. The study was approved by the Human Investigations Committee of Yale School of Medicine. 51 patients had type 1 GD with at least one N370S (pArg409Ser) mutation in GBA gene, mean age 63.9 years (range 40–93 years). Patients were stratified into young and older patients with mean age 11.25 years vs. 55.8 years. Five patients had GD type 3 (homozygous for L444P mutation, pLeu483Leu). The mean age of 28 healthy controls was 38 years.</p></sec><sec id="s2-2"><title>Mice</title><p>Mice were housed in the animal facility of Yale University in New Haven. All animal experiments were conducted in compliance with institutional regulations under authorized protocol (2016-10872) approved by the Institutional Animal Care and Use Committee. <italic>Gba</italic><sup>lsl/lsl</sup> mice or <italic>Krt14</italic><sup>lnl/lnl</sup> were generated as described previously (<xref ref-type="bibr" rid="bib20">Enquist et al., 2007</xref>). We refer to <italic>Gba</italic><sup>lsl/lsl</sup> as nGD mice throughout the text. We used <italic>Krt14</italic><sup>Cre</sup> (strain #: 018964), <italic>Cx3cr1</italic> Cre (strain #: 025524), and <italic>Nes</italic>tin Cre (strain #: 003771) obtained from Jackson Laboratories. For breeding purpose, we used <italic>Gba</italic><sup>lnl/wt</sup> mice (gift from Sanofi Genzyme) that were then crossed with <italic>Krt14</italic><sup>Cre/Cre</sup> (Jackson Laboratories) to obtain <italic>Gba</italic><sup>lsl/wt</sup> <italic>Krt14</italic><sup>cre/cre</sup>. These mice were used as parents to obtain nGD, <italic>Gba</italic><sup>lsl/wt</sup>, and <italic>Gba</italic><sup>wt/wt</sup> pups. nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> and nGD <italic>Nes</italic><sup>Cre/+</sup> were obtained by breeding these parents on to <italic>Cx3cr1</italic> Cre and <italic>Nes</italic>tin Cre. <italic>Gba</italic><sup>fl/fl</sup><italic>Cx3cr1</italic><sup>cre</sup> mice were generated by crossing <italic>Gba</italic><sup>fl/fl</sup> (<xref ref-type="bibr" rid="bib37">Mistry et al., 2010</xref>) with <italic>Cx3cr1</italic> Cre mice obtained from Jackson Laboratories. Mice of both sexes were used for the study. From postnatal day 8, C57BL/6J mice (Jackson Laboratories, USA) were injected intraperitoneally (i.p.) daily with 25 mg conduritol β-epoxide (CBE) (Calbiochem Millipore, Darmstadt, Germany) per kilogram body weight, or with phosphate-buffered saline (PBS) (<xref ref-type="bibr" rid="bib57">Vardi et al., 2020</xref>). Newborn mice were gavaged daily with 5 mg/kg of GZ 161 once a day starting at postnatal day 4 (<xref ref-type="bibr" rid="bib11">Cabrera-Salazar et al., 2012</xref>). To determine whether further benefits could be achieved by prenatal exposure to GZ 161, a subset of mice also received GZ 161 in food using a formulation calculated to provide 20 mg/kg/day.</p><sec id="s2-2-1"><title>Brain tissue harvesting and cell preparation</title><p>The complete brain was cut into small pieces and incubated with digestion buffer (RPMI supplemented with 2% FBS, 2 mM HEPES, 0.4 mg/ml Collagenase D, and 2 mg/ml DNase) for 30 min at 37°C under shaking. To stop enzymatic digestion, EDTA 5 mM was used and the sample was homogenized with a syringe. This was then followed by gradient centrifugation, and cell separation was achieved via Percoll gradients (GE Healthcare Life Sciences) of various densities (<xref ref-type="bibr" rid="bib33">Lee and Tansey, 2013</xref>). Myelin was then removed by vacuum suction and cells were isolated from the interphase. The interphase was diluted with 10 ml of HBSS and centrifuged at 500 × <italic>g</italic> for 7 min to obtain cell pellet that was used for cellular analysis.</p></sec><sec id="s2-2-2"><title>Flow cytometry</title><p>Flurochrome-labeled antibodies used for the flow cytometry are listed in the Key resources table. In brief, surface staining was performed ex vivo using antibodies to CD11b, CD45, Gr-1, CD3, CD8, CD4, CD103, CD69, and NK1.1 (BD Biosciences); ACSA-2 antibody (Miltenyi Biotech). For staining of the intracellular antigens, GZM-A and Pro IL-1β (BD Biosciences) cells were stimulated with cell stimulation cocktail (eBioscience) for 4 hr. After surface staining with antibodies, cells were fixed and permeabilized using BD cytofix and Cytoperm and antibodies recognizing GZM-A and Pro IL-1β.</p></sec></sec><sec id="s2-3"><title>Sorting of cells by flow cytometry</title><p>Isolated total brain cells were resuspended at 1 million cells/ml of PBS and Live/Dead Fixable Violet Dead Cell Stain (Thermo Fisher) for 10  min to exclude nonviable cells. Cells were washed once in excess PBS, and then, cells were suspended in ice-cold FACS buffer (10% FBS in PBS with 1% HEPES + 0.5% EDTA) and stained with anti-mouse CD45 and anti-mouse CD11b antibody (BD Pharmingen) for 30 min at 4°C. All cells were washed twice with FACS buffer and sorted into polypropylene tubes with 500 μl of ice-cold FACS buffer. All samples were acquired on the BD FACS Aria.</p><sec id="s2-3-1"><title>Single-cell RNA sequencing (scRNA-seq)</title><p>All cells were prepared through 10X Genomics V3 3′ Gene Expression kit and sequenced on NovaSeq flow cells to achieve high read depth. We used the preprocessed digital gene expression matrices as obtained from cell ranger (as run by the YCGA sequencing core facility). These matrices were processed using Seurat (<xref ref-type="bibr" rid="bib47">Satija et al., 2015</xref>). The clusters were determined using Louvain algorithm for community detection (<xref ref-type="bibr" rid="bib58">Vincent et al., 2008</xref>). Differential gene expression between the clusters was carried out using the MAST method (<xref ref-type="bibr" rid="bib22">Finak et al., 2015</xref>). The visualizations and analysis were carried out in R (R Core Team). The data were visualized as t-distributed stochastic neighbor embedding (t-SNE) (<xref ref-type="bibr" rid="bib27">Hinton, 2002</xref>). From 14-day pups, we sequenced a total of 4895 CD45+ cells. For GZ161 treatment experiments, we sequenced a total of 40,763 CD45+ cells that consists of four groups of mice with three mice per each group.</p></sec><sec id="s2-3-2"><title>Subsetting of microglia cells</title><p>Based on the clustering of CD45<sup>+</sup> cells, clusters 1, 16, and 26 were kept for final analysis. The clusters were selected based on the microglial gene expression. The clusters comprised 4230 cells. Scoring used z-scores of homeostatic microglia genes, DAM genes from <xref ref-type="bibr" rid="bib62">Wang et al., 2020</xref>.</p></sec><sec id="s2-3-3"><title>Single-nuclear RNA sequencing (snRNA-seq)</title><sec id="s2-3-3-1"><title>Nuclei isolation</title><p> Brain tissue samples were stored at –80°C. For tissue lysis and washing of nuclei, sample sections were added to 1 ml lysis buffer (Nuclei PURE Lysis Buffer, Sigma) and thawed on ice. Samples were then Dounce homogenized with PestleAx20 and PestleBx20 before transfer to a new tube, with the addition of additional lysis buffer. Following incubation on ice for 15 min, samples were then filtered using a 30 μM MACS strainer (MACS strainer, Fisher Scientific), centrifuged at 500 × <italic>g</italic> for 5 min at 4°C using a swinging bucket rotor (Sorvall Legend RT, Thermo Fisher), and then pellets were washed with an additional 1 ml cold lysis buffer and incubated on ice for an additional 5 min. Lysates were combined with 1.8 ml of a 1.8 M sucrose solution (Nuclei PURE Sucrose Buffer, Sigma) containing 1 mM DTT and 0.2 U RNAse inhibitor and mixed by inversion. Samples were then layered on top of a 1.8 M sucrose layer to form a gradient and centrifuged at 30,000 × <italic>g</italic> for 45 min at 4°C using a swinging bucket rotor. The supernatant was removed, and nuclei pellets were resuspended in 1 ml of a 1× PBS wash buffer containing 1% BSA and 0.2 U RNAse inhibitor. Samples were centrifuged again at 500 × <italic>g</italic> for 5 min at 4°C and the supernatant removed. Nuclei were resuspended in 0.5 ml wash buffer and counted using Countess (Life Technologies) prior to 10X Genomics protocol. For samples that were enriched using flow cytometry, nuclei were stained with 20 μg/ml DAPI for 30 min on ice with occasional mixing. Nuclei were centrifuged at 500 × <italic>g</italic> for 5 min at 4°C. The supernatant was removed, and pellet resuspended in 800 μl of a 1× PBS wash buffer containing 1% BSA, 1 mM EDTA, and 0.2 U RNAse inhibitor. Nuclei were sorted using the BD Influx by first gating on forward/side scatter then on DAPI-positive nuclei. The collected nuclei were centrifuged, then resuspended in ~200 µl 1× PBS wash buffer containing 1% BSA and 0.2 U RNAse inhibitor and counted using Countess (Life Technologies) prior to 10X Genomics protocol.</p></sec><sec id="s2-3-3-2"><title>Library preparation and NovaSeq sequencing</title><p>Libraries were prepared according to 10X Genomics protocol using the Chromium Next GEM Single Cell 3′ Reagents Kit V3.1 (Dual Index) for encapsulation, mRNA capture, cDNA synthesis/amplification, and library construction. Final libraries were quantified using the DNA High Sensitivity Kit (Agilent Bioanalyzer 2100) and Qubit 2.0 (Life Technologies). Libraries were diluted to 1.5 nM, then pooled prior to sequencing on the Illumina NovaSeq6000. UMI count matrices were generated with  Cell Ranger V3.0.2.</p></sec><sec id="s2-3-3-3"><title>Data preprocessing</title><p> Summary information for final UMI count matrices for nuclei by individual sample and sequencing data is presented in (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A, C</xref>). Count matrices together with nucleus barcodes and gene labels were loaded with R version 3.6.1/RStudio for sample integration and unsupervised clustering using Seurat Package version 3.1. For quality control (QC), nuclei were filtered following standard protocols based on examination of violin plots. Cutoffs were used, and the filtered matrices were then individually log-normalized by sample according to standard Seurat workflows. After quality filtering, total nuclei were included in the final data analysis.</p></sec><sec id="s2-3-3-4"><title>Broad cell-type annotation</title><p>Sample integration was performed in Seurat using the  Find Integration Anchors and Integrate Data functions for variable features. Following integration and scaling according to Seurat package workflows, a range of clustering resolution values were trialed prior to broad cell-type annotation; UMAP, t-SNE plots for broad types annotation included. Cluster-level expression of major cell type markers was examined and used to annotate cells contained within each cluster. Clustering resolution achieved separation and consistency of cell-type marker expression.</p></sec><sec id="s2-3-3-5"><title>Differential gene expression and pathway enrichment analysis</title><p> Genes differentially expressed between conditions within clusters may reveal pathway alterations specific to the clustered cell type. To profile cluster-level pathway enrichment patterns, cluster-level differentially expressed genes were identified using the Seurat Find Markers function with the MAST package. Markers used for downstream functional analysis were those with adjusted p-value &lt;0.05. Functional ontology analysis by cluster was performed for each cluster marker set using ingenuity pathway analysis (IPA) (enrichment-adjusted p-value &lt; 0.05).</p></sec><sec id="s2-3-3-6"><title>Total RNA-seq</title><p>mRNA sequence data were uploaded to a high-performance computing system with PartekFlow software (v7.0, Partek, St. Louis, MO), adapter trimmed and remapped to mouse genome, mm10 using STAR v2.5.3a aligner with default setting (Phred:20) for read mapping. Statistical analysis was carried out using false discovery rate (FDR) correction through the Benjamini–Hochberg method.</p></sec><sec id="s2-3-3-7"><title>BrdU retention assay</title><p>The assay was performed as described earlier (<xref ref-type="bibr" rid="bib56">Takizawa et al., 2011</xref>); briefly mice were i.p. injected with 180 μg BrdU (sigma) and were fed water containing 800 μg/ml BrdU and 4% glucose for 12 days. Mice were then sacrificed, organs (brain and spleen) were removed, and cells were isolated as described earlier. BrdU staining was performed using BrdU labeling kit (BD). Cells from normal water-fed mice were used as staining controls.</p></sec><sec id="s2-3-3-8"><title>Mouse serum Nf-L assay</title><p>Quanterix Nf-L assays were performed in triplicate according to the manufacturer’s protocols using the Nf-Light Advantage kit on a single-molecule array (SIMOA) HD-X instrument (Quanterix, Lexington, MA).</p></sec><sec id="s2-3-3-9"><title>Lipidomics</title><p>Separation of glucosylceramides and galactosyl ceramides was performed by SFC-MS/MS analyses at the MUSC Lipidomics Shared Resource. The equipment consisted of a Waters UPC 2 system coupled to a Thermo Scientific Quantum Access Max triple quadrupole mass spectrometer equipped with an ESI probe operating in the multiple reaction monitoring-positive ion mode tuned and optimized for the Waters UPC 2 system.</p></sec><sec id="s2-3-3-10"><title>Brain tissue slide preparation and MALDI-MS imaging</title><p>Brain tissues were dissected, divided sagittally into halves and immediately placed in Cryomolds (Tissue-Tek) containing 10% gelatin-water (porcine skin, Sigma-Aldrich, #G1890), placed at 37°C on the heating block, and transferred to the cryomold into dry-ice bath. Cryo-sectioning was performed at a chamber temperature of –20°C with 12 µm thickness. Sections were thaw-mounted onto the ITO-coated side with barcoding of MALDI IntelliSlides (Bruker, Cat# 1868957). Slides were stored at –80°C until time for imaging. An optical image for tissue sections was obtained using TissueScout scanner (Bruker). Once the optical image was obtained, it was transferred to the HTX Sublimator (HTX Technologies, Chapel Hill, NC) for matrix deposition. DHB (2,5-dibydroxybenzoic acid) was applied on the tissue sections by sublimation, which was performed according to the HTX Sublimator setting (2 ml of 40 mg/mL DHB in acetone transfer solvent, 60°C preheat temperature, 160°C final temperature, 200 s). MALDI-MS imaging was performed in positive ion mode over a mass range of m/z 300–1300 on a Bruker timsTOF fleX mass spectrometer equipped with a 10 kHz SmartBeam 3D Nd:YAG (355 mm) laser. Imaging was performed using a laser raster size of 20 µm custom setting, 20 µm scan range, with trapped ion mobility mode On (tims‘ON’) for cross-sectional collision values with the following parameters: 1/K<sub>o</sub> start at 0.90 V.s/cm<sup>2</sup> and end 1.70 V.s/cm<sup>2</sup>, ramp time at 150 ms, accumulation time 40.0 ms, duty cycle 26.67%, ramp rate 6.50 Hz. Spectra were accumulated from 400 laser shots with the laser power percentage adjusted using the highest peak (m/z 760 positive ion mode) intensity between 10<sup>4</sup> and 10<sup>5</sup>, and the method was saved for all subsequent acquisitions. For each image acquisition, the instruments were calibrated using ESI-L Low concentration tuning mix (Agilent Technologies, Cat #G1969-85000). Data were analyzed using SCiLs Lab MALDI imaging software package, version 2021b (Bruker), with data normalized to the TIC. Targeted analysis for hexceramides, sphingomyelins, and phosphatidylcholines was analyzed for differential changes between animals.</p></sec></sec></sec><sec id="s2-4"><title>Lipid extraction of mouse serum</title><p>To quantify GlcSph, 7 μl of mouse serum was aliquoted into a labeled 1.5 ml Eppendorf tube followed by 100  μl of internal standard solution (12 ng/ml dimethyl-psychosine, 80% methanol, 20% acetonitrile with 10 mM ammonium acetate, and 1% formic acid). The samples were vortexed for 5 min and sonicated for 10 min. The tubes were centrifuged at 13,000 × <italic>g</italic> for 5 min at room temperature (RT). The supernatant from each tube was transferred into a pre-labeled total recovery MS vial. Calibration curves for GlcSph were prepared in a pooled control serum, and concentrations of lysoGL1 were from 0.1 to 1000  ng/ml.</p></sec><sec id="s2-5"><title>Mass spectrometry analysis of GlcSph</title><p>Mouse serum was first tested on a Hilic- method to separate psychosine (steroisomer of GlcSph) and GlcSph and confirm that psychosine does not interfere with the quantitation of mouse serum glucosylsphingosine levels (Wei-Lien Chuang et al.). The supernatant was injected (5  μl) into an LC/MS/MS system comprised of an Acquity UPLC (Waters, Milford, MA) and Sciex Triple Quad 5000 mass spectrometer (Sciex, Toronto, Canada). The chromatographic separation was achieved with a Waters Acquity BEH C18 column (2.1 ∗ 150  mm, 1.7  μm) using mobile phases: (A) water with 0.1% formic acid and (B) 85:15 MeOH:ACN with 0.1% formic acid. The column was maintained at 60°C. GlcSph was eluted with the following gradient: from 50% B to 99% B over 2 min, then the mobile phase composition was hold constant for 1 min followed by a rapid return (0.1 min) to 50% B maintained for 0.5 min. All experiments were carried out at a flow rate of 0.5 ml/min. Data were analyzed in Analyst (AB Sciex, Toronto, Canada).</p><sec id="s2-5-1"><title>Behavioral studies</title><sec id="s2-5-1-1"><title>Balance beam test</title><p>Evaluating fine motor coordination using balance beam (1 mt) with 12 mm width resting 50 cm above the top of the pole. The time to cross each beam was recorded and compared between mouse strains.</p></sec></sec></sec><sec id="s2-6"><title>Open field</title><p>Mouse locomotor behavior was assessed using the open field (<xref ref-type="bibr" rid="bib17">Crusio, 2001</xref>). Mice were individually placed on the 28 × 28 cm plate surrounded by plastic walls in a well-lit room and allowed to freely explore for 10 min. Spatial statistic, total distance travel, area measure, and time spent in the center of the square were quantified. The movements were recorded with a video tracking system and stored on a computer.</p></sec><sec id="s2-7"><title>BODIPY staining</title><p>Isolated total mice brain cells from nGD and age-matched control mice were prepared (as described in the section ‘Brain tissue harvesting and cell preparation’) and stained with CD45, CD11b, and ACSA-2, then incubated in PBS with BODIPY 493/503 (1:1000 from a 1 mg/ml stock solution in DMSO; Thermo Fisher) for 10 min at RT, washed twice in PBS, and BODIPY intensity was analyzed on LSRII instrument (BD Biosciences).</p></sec><sec id="s2-8"><title>ROS assay</title><p>To assess ROS generation in astrocytes and microglia from nGD mice, isolated total mice brain cells were stained with CD45, CD11b, and ACSA-2 followed by incubation in FACS buffer with CellROX Deep Red (1:500; Invitrogen) for 30 min at 37°C, washed twice in FACS buffer, and CellROX Deep Red Intensity was analyzed on LSRII instrument (BD Biosciences).</p></sec><sec id="s2-9"><title>ApoE measurement</title><p>ApoE levels in sera of GD patients were measured by ELISA using Abnova Cat# KA1031 following the manufacturer’s instructions. A dilution of 1:400 sera was used.</p></sec><sec id="s2-10"><title>Quantification and statistical analysis</title><p>Data were routinely presented as mean ± SEM. Statistical significance was determined using <italic>t</italic>-test using Bonferroni–Dunn correction for multiple comparisons. Differences between groups were analyzed using Student’s <italic>t</italic>-test using GraphPad Prism 8.0. For the Kaplan–Meier analysis of survival, the log-rank (Mantel–Cox) test was performed.</p></sec><sec id="s2-11"><title>Study approval</title><p>All animal experiments were conducted in compliance with institutional regulations under authorized protocol (2016-10872) approved by the Institutional Animal Care and Use Committee. The study was approved by the Human Investigations Committee of Yale School of Medicine, and written informed consent was received prior to participation.</p><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Reagents</th><th align="left" valign="top">Supplier name</th><th align="left" valign="top">Cat#</th><th align="left" valign="top">Clone</th></tr></thead><tbody><tr><td align="left" valign="top">CD11b</td><td align="left" valign="top">BD Biosciences</td><td align="char" char="." valign="top">583553</td><td align="left" valign="top">M1/70</td></tr><tr><td align="left" valign="top">CD11b</td><td align="left" valign="top">BD Biosciences</td><td align="char" char="." valign="top">552850</td><td align="left" valign="top">M1/70</td></tr><tr><td align="left" valign="top">ACSA-2</td><td align="left" valign="top">Miltenyi Biotech</td><td align="char" char="hyphen" valign="top">130-123-284</td><td align="left" valign="top">IH3-18A3</td></tr><tr><td align="left" valign="top">CD45</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">103133</td><td align="char" char="hyphen" valign="top">30-F11</td></tr><tr><td align="left" valign="top">NK1.1</td><td align="left" valign="top">BD Biosciences</td><td align="char" char="." valign="top">562864</td><td align="left" valign="top">PK136</td></tr><tr><td align="left" valign="top">CCR2</td><td align="left" valign="top">R&amp;D</td><td align="left" valign="top">FAB5538F</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">CD3</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">100241</td><td align="char" char="." valign="top">17A2</td></tr><tr><td align="left" valign="top">NK1.1</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">108753</td><td align="left" valign="top">PK136</td></tr><tr><td align="char" char="." valign="top">1A/1-E</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">107639</td><td align="left" valign="top">M%/114.152</td></tr><tr><td align="left" valign="top">CD4</td><td align="left" valign="top">BD Biosciences</td><td align="char" char="." valign="top">563790</td><td align="left" valign="top">GK1.5</td></tr><tr><td align="left" valign="top">CD4</td><td align="left" valign="top">BD Biosciences</td><td align="char" char="." valign="top">558107</td><td align="left" valign="top">RM4-5</td></tr><tr><td align="left" valign="top">Gr-1</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">108440</td><td align="left" valign="top">RB6-8c5</td></tr><tr><td align="left" valign="top">Ly-6C</td><td align="left" valign="top">Invitrogen</td><td align="char" char="hyphen" valign="top">47-5932-82</td><td align="left" valign="top">HK1.4</td></tr><tr><td align="left" valign="top">CD64</td><td align="left" valign="top">BioLegend</td><td align="char" char="." valign="top">139306</td><td align="left" valign="top">X54-5</td></tr><tr><td align="left" valign="top">B220</td><td align="left" valign="top">eBioscience</td><td align="char" char="hyphen" valign="top">47-0452-80</td><td align="left" valign="top">RA3-6B2</td></tr><tr><td align="left" valign="top">CD8a</td><td align="left" valign="top">eBioscience</td><td align="char" char="hyphen" valign="top">56-0081-82</td><td align="char" char="ndash" valign="top">53-6.7</td></tr><tr><td align="left" valign="top">Brdu Flow kit</td><td align="left" valign="top">BD Pharmingen</td><td align="char" char="hyphen" valign="top">51-9000019AK</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">5-Bromo-2'-deoxyuridine</td><td align="left" valign="top">Cayman Chemical Company</td><td align="char" char="." valign="top">15580</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">Cell Rox Deep Red</td><td align="left" valign="top">Invitrogen</td><td align="left" valign="top">C10422</td><td align="left" valign="top"/></tr><tr><td align="left" valign="top">IL-1Beta</td><td align="left" valign="top">Invitrogen</td><td align="char" char="hyphen" valign="top">17-7114-80</td><td align="left" valign="top">NTTEN3</td></tr></tbody></table></table-wrap></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Glycosphingolipid-laden microglial activation and immune cell infiltration drive GD-associated neurodegeneration</title><p>We performed temporospatial analysis of brain in nGD mice (<italic>Gba</italic><sup>lsl/lsl</sup> mice with germline deletion of <italic>Gba,</italic> rescued from lethal skin phenotype using <italic>Krt14</italic><sup>Cre</sup>) compared to control mice (<italic>Gba</italic><sup>lsl/wt</sup> and <italic>Gba</italic><sup>wt/wt</sup>) on days 2, 4, 8, 10, and 14. nGD mice looked clinically well during the first week and subsequently developed progressive ataxia, weight loss, and hind limb paralysis, by day 14, as described previously (<xref ref-type="bibr" rid="bib20">Enquist et al., 2007</xref>). Microglia and macrophage subsets in brain were defined by combinatorial expression of CD11b, CD45, T cell immunoglobulin and mucin domain containing 4 (TIMD4), and the chemokine receptor C-C motif chemokine receptor 2 (CCR2). Brain microglia have self-renewal capacity with minimal monocyte input in contrast to CCR2<sup>+</sup> macrophages, which have limited self-renewal capacity and are constantly replaced by blood monocytes (<xref ref-type="bibr" rid="bib19">Dick et al., 2022</xref>). Infiltration of CCR2<sup>+</sup> macrophages (MFs) defined as CD11b<sup>hi</sup> CD45<sup>+</sup>CCR2<sup>+</sup> CD64<sup>+</sup> TIMD4<sup>-</sup> population (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>) was noted in the nGD brain from an early time point day 2, which showed a steady increase until day 14 when the mice reached the humane end point (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Concurrently, there was attrition of homeostatic microglia and incremental infiltration of diverse immune cells into nGD brains, which coincided with mice displaying clear signs of neurodegeneration (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). The predominant immune cells in healthy mouse brains were homeostatic microglia, as expected, whereas in nGD brains, the repertoire of immune cells comprised diverse lymphoid (T cells, NK cells, ILC-2, pDC), and myeloid compartment (cDC, monocytes, and/or macrophages) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>). To investigate the metabolic consequences of <italic>Gba</italic> deletion in microglia and infiltrating immune cells, we performed HPLC/MS/MS on flow-sorted microglia and infiltrating immune cells. Microglia from nGD brains harbored elevated levels of GluCer species (C16, C18, and C20), as well as GlcSph. Notably, the immune cell infiltrates in the nGD brains were also enriched in glucosylceramides (C16 and C18) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1C</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Loss of <italic>Gba</italic> induces microglial activation and immune cell infiltration in neuronopathic Gaucher disease (nGD) brain.</title><p>(<bold>A</bold>) Fluorescence-activated cell sorting (FACS) analysis of the whole brain of <italic>Gba</italic><sup>wt/wt</sup>, <italic>Gba</italic><sup>lsl/wt</sup>, and nGD (<italic>Gba</italic><sup>lsl/lsl</sup>) mice performed at indicated days. The gates indicate cell populations revealed by CD11b and CD45 expression: CCR2<sup>+</sup> MFs (CD11b<sup>hi</sup>CD45<sup>+</sup>), microglia (CD11b<sup>lo</sup>CD45<sup>+</sup>), and immune infiltrates (CD11b<sup>lo</sup>CD45<sup>hi</sup>). The data is representative of three independent experiments. (<bold>B</bold>) Bar graph compares percentage of CCR2<sup>+</sup> MFS, microglia, and immune infiltrates between <italic>Gba</italic><sup>wt/wt</sup>, <italic>Gba</italic><sup>lnl/wt</sup>, and nGD mice brain (n = 6–8 mice/group); statistical significance was determined using <italic>t</italic>-test with using Bonferroni–Dunn correction for multiple comparisons (***p&lt;0.0001). (<bold>C</bold>) t-distributed stochastic neighbor embedding (t-SNE) plot depicting different microglial and non-microglial cell subsets. The clusters are coded based on their mice affiliation (on left). In total, 14 clusters containing 6 microglia clusters and 9 clusters of immune cells (on right). (<bold>D</bold>) Hierarchical clustering of differentially expressed genes associated with type 1 IFN genes from nGD mice vs. the control mice. p&lt;0.05 was considered significant (two-sided <italic>t</italic>-tests). All individual type 1 IFN genes with significant differential expression are listed on right. Error bars represent means ± SEM; p-values were calculated with Welch’s test (**p&lt;0.001 and ***p&lt;0.0001).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Loss of <italic>Gba</italic> disrupts microglial homeostasis and induces damage-associated microglia (DAM) phenotype and immune cell infiltration in neuronopathic Gaucher disease (nGD) (<italic>Gba</italic><sup>lsl/lsl</sup>) brain.</title><p>(<bold>A</bold>) Representative fluorescence-activated cell sorting (FACS) plot showing CCR2<sup>+</sup> MFs, microglia, and immune infiltrates in the whole brain of nGD vs. control mice brain. (<bold>B</bold>) Bar graph shows the frequency of different immune cells (denoted on right) in the immune infiltrates obtained from neuronopathic GD (nGD; <italic>Gba</italic><sup>lsl/lsl</sup>) and control mice brain, respectively. (<bold>C</bold>) Bar graph shows quantitative analysis of total glucosylceramide (GluCer) species and glucosylsphingosine (GlcSph) levels by LC-ESI-MS/MS in flow-sorted microglia cells obtained from Gba<sup>wt/wt</sup>, Gba<sup>lsl/wt</sup>, and nGD brains and on immune infiltrates isolated from nGD brain. (<bold>D</bold>) t-distributed stochastic neighbor embedding (t-SNE) plot demonstrating annotations of different clusters identified using expression of signature genes. (<bold>E</bold>) Hierarchical heat map representing the differentially expressed genes in each identified cluster.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Total RNA-seq analysis performed on flow-sorted microglia in neuronopathic Gaucher disease (nGD) (<italic>Gba</italic><sup>lsl/lsl</sup>) and wild-type mice.</title><p>(<bold>A</bold>) Principal component analysis of gene expression profiles of microglia isolated from nGD brain and their controls. Each point represents a single mouse. (<bold>B</bold>) A heat map showing the differential expression of homeostatic and disease-associated microglial (DAM) genes in isolated microglia from nGD and control mice brain, respectively. (<bold>C</bold>) A heat map of interferon signature genes (ISG) genes in isolated microglia from nGD and control mice brain, respectively. Colors indicate upregulated (red) and downregulated genes (green).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig1-figsupp2-v2.tif"/></fig></fig-group><p>For de novo characterization of the brain immune cell microenvironment, sorted CD45<sup>+</sup> cells from nGD and control brains were analyzed by scRNA-seq. Dimensionality reduction using t-distributed stochastic neighbor embedding (t-SNE) analysis revealed 15 distinct cellular clusters of CD45<sup>+</sup> cells (numbered 0–14) (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). We assigned these clusters to individual immune subsets based on the expression of known marker genes (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D and E</xref>). There were major alterations in the immune cell composition in nGD brains, which was qualitatively and quantitatively dominated by various lymphocyte populations (T cells, γδT cells, Treg cells, NK cells, and ILC-2), pDC, and a heterogenous myeloid compartment (cDC, monocytes/macrophages, and granulocytes) (<xref ref-type="fig" rid="fig1">Figure 1C</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1D</xref>). Homeostatic microglia were reduced in nGD brains, consistent with impaired microglial homeostasis in nGD pathology (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A and D</xref>). Interestingly, the B cell population (cluster 4) appeared more pronounced in nGD brains, although it was also present in controls. The microglia and immune cell infiltrates in nGD brains exhibited a striking upregulation of type 1 interferon signature genes (ISG) (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Total RNA-seq analysis performed on flow-sorted microglia from nGD and control mice revealed distinct gene expression profiles in GluCer/GlcSph-laden nGD microglia vs. control microglia (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref>). Microglia of nGD mice exhibited clear downregulation of homeostatic genes and concomitant upregulation of disease-associated microglia (DAM) signature genes, in addition to upregulation of ISGs (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2B and C</xref>). Together, these findings establish GluCer/GlcSph-laden DAM, and peripheral immune cell infiltration as key features of nGD neuropathology.</p></sec><sec id="s3-2"><title><italic>Gba</italic> restoration in microglia and neurons prolongs survival of nGD mice</title><p>To dissect the contribution of microglia and neurons in nGD neurodegeneration, we generated nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> and nGD <italic>Nes</italic><sup>Cre/+</sup> mice for selective rescue of <italic>Gba</italic> in microglia and neurons, respectively (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Unless otherwise stated, we used littermate <italic>Gba</italic><sup>wt/wt</sup> with the respective Cre recombinases as controls. Notably, restoration of <italic>Gba</italic> in microglia (nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice) led to more than twofold increase in survival compared to nGD mice (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Selective restoration of <italic>Gba</italic> in neurons (nGD <italic>Nes</italic><sup>Cre/+</sup> mice) further enhanced the survival up to ~200 days where they reached the humane end point (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). To assess the alterations in microglia and macrophage phenotypes associated with targeting of <italic>Gba</italic> in microglia/neurons, we compared the brains of nGD, nGD <italic>Cx3cr1</italic><sup>Cre/+</sup>, and nGD <italic>Nes</italic><sup>Cre/+</sup> mice. Restoration of <italic>Gba</italic> in microglia of nGD mice (nGD <italic>Cx3cr1</italic><sup>Cre/+</sup>) resulted in increased homeostatic microglia with reduction in CCR2<sup>+</sup> MFs and peripheral immune cell infiltration compared to nGD brains (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>). In contrast, restoration of <italic>Gba</italic> in neurons of nGD mice (nGD <italic>Nes</italic><sup>Cre/+</sup>) blocked attrition of microglia as well as the infiltration of CCR2<sup>+</sup> MFs and peripheral immune cells (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Correspondingly, induction of intracellular Pro-IL-1ß in microglia, an indicator of microglial activation, was observed in both nGD and nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> brains (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>) but not in nGD <italic>Nes</italic><sup>Cre/+</sup> brains (<xref ref-type="fig" rid="fig2">Figure 2D and F</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>). Collectively, these data establish the critical role of <italic>Gba</italic> deficiency in neurons in aiding vigorous microglial activation and immune cell infiltration in nGD and nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> brains. Consistent with this notion, compared to nGD mice, both nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice and nGD <italic>Nes</italic><sup>Cre/+</sup> mice showed striking reduction of brain glucosylceramides (by ≥90% for C16 and C18:1, and by 50–70% for C18, C20:1, C22, C22.1, C24, and C24:1, and by 38% for C20 glucosylceramide) with a concomitant, striking reduction of GlcSph (89–98%, shown in <xref ref-type="fig" rid="fig2">Figure 2G</xref>). We depict this data, as fold elevation compared to wild-type mice brains, of various glucosylceramides in nGD and after <italic>Gba</italic> rescue in microglia and neurons in <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>, which provides insight into relative contributions of microglia and neurons in the accumulation of the lipids in nGD. First, in <italic>Gba</italic> deficiency, the microglia display impressive capacity to process accumulating glucosylceramides, and second, that the major source of accumulating glucosylceramides in nGD appears to be the neuronal compartment. This is illustrated by the observation that compared to wild-type mice brains, in nGD mice, there is a 200-fold elevation of brain C16-glucosylceramide, which falls to 5-fold elevation after microglia rescue and to 2.4-fold after neuronal rescue of <italic>Gba</italic>. Similar gradations are seen for brain GlcSph accumulation: 200-fold vs. 20-fold vs. 7-fold, respectively. Together, these observations suggest that reduced sphingolipid turnover observed in nGD <italic>Nes</italic><sup>Cre/+</sup> mice may exert a positive effect on overall microglial maintenance regardless of microglia cell intrinsic <italic>Gba</italic> deficiency. It seems likely that diverse inflammatory responses triggered by sphingolipid-induced neuronal damage observed in nGD and nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> brains could directly impact microglial maintenance and cell death.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>Gba</italic> deficiency in neurons aid in microglial activation and immune cell infiltration.</title><p>(<bold>A</bold>) Schematic showing overview of the mouse models and methods used in the study. (<bold>B</bold>) Kaplan–Meier survival analysis of neuronopathic Gaucher disease (nGD), nGD <italic>Cx3cr1</italic><sup>Cre/+</sup>, and nGD <italic>Nes</italic><sup>Cre/+</sup> mice cohorts with their respective littermate controls (n = 5–6 mice/group) using log-rank (Mantel–Cox) test (***p&lt;0.0001). (<bold>C</bold>) Bar graph shows comparison of percentage of CCR2<sup>+</sup> MFs, microglia and immune infiltrates between nGD, nGD <italic>Cx3cr1</italic><sup>Cre/+</sup>, and nGD <italic>Nes</italic><sup>Cre/+</sup> mice with littermate controls (n = 3–6 mice/group). Bar graph showing percentage of Pro-IL-1ß<sup>+</sup> microglia cells in (<bold>D</bold>) nGD vs. control mice (n = 5–6/group), (<bold>E</bold>) nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> vs. control mice (n = 5–6/group), and (<bold>F</bold>) nGD <italic>Nes</italic><sup>Cre/+</sup> vs. the control mice (n = 3 mice/group). (<bold>G</bold>) Quantitative analysis of total glucosylceramide (GluCer) species and glucosylsphingosine (GlcSph) levels by LC-ESI-MS/MS in nGD, nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice, and nGD <italic>Nes</italic><sup>Cre/+</sup> mice brain compared with the control mice (n = 4–8 mice/group). (<bold>C–G</bold>) show representative data from two independent experiments using controls. Means ± SEM are shown. Unpaired <italic>t</italic>-test, two-tailed was used to test significance. *p&lt;0.05, **p&lt;0.001, and ***p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Restoring <italic>Gba</italic> function in microglia and neurons enhances neuronopathic Gaucher disease (nGD) mice survival.</title><p>(<bold>A</bold>) Splicing of mRNA causes GBA1 deficiency in nGD mice. K14-mediated expression of Cre enabled removal of the lsl (lox-stop-lox) cassette in the skin tissue of the nGD mice (left and bottom panels), <italic>Cx3cr1</italic><sup>Cre</sup> enabled removal of the lsl cassette in different tissues (middle and bottom panels), and Nestin Cre enabled removal of the lsl cassette in brain (right and bottom panels). (<bold>B</bold>) Representative fluorescence-activated cell sorting (FACS) plot showing CCR2<sup>+</sup> MFs, microglia, and immune infiltrates in the whole brain of nGD, nGD <italic>Cx3cr1</italic><sup>Cre/+</sup>, and nGD <italic>Nes</italic><sup>Cre/+</sup> mice vs. control mice brain. (<bold>C</bold>) Representative intracellular staining for Pro-IL-1ß expression in microglia isolated from nGD, nGD <italic>Cx3cr1</italic><sup>Cre/+</sup>, and nGD <italic>Nes</italic><sup>Cre/+</sup> and control mice analyzed by FACS.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Gel image showing genotype of neuronopathic Gaucher disease (nGD), Het, and wild-type (wt).</title><p>The lsl (lox-stop-lox) cassette in nGD mice (left panel) was removed through to <italic>Krt14</italic><sup>cre</sup> expression (right panel).</p></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-79830-fig2-figsupp1-data1-v2.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Gel image showing genotype of neuronopathic Gaucher disease (nGD) <italic>Cx3cr1</italic><sup>Cre/+</sup> and wild-type (wt) mice.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-79830-fig2-figsupp1-data2-v2.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata3"><label>Figure 2—figure supplement 1—source data 3.</label><caption><title>Gel image showing genotype of nGD <italic>Nes</italic><sup>Cre/+</sup> mice and wild-type (wt) mice.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-79830-fig2-figsupp1-data3-v2.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata4"><label>Figure 2—figure supplement 1—source data 4.</label><caption><title>Gel image showing removal of lsl (lox-stop-lox) cassette in neuronopathic Gaucher disease (nGD) mice in various tissues due to <italic>Krt14</italic><sup>cre</sup> expression.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-79830-fig2-figsupp1-data4-v2.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata5"><label>Figure 2—figure supplement 1—source data 5.</label><caption><title>Gel image showing Cx<italic>3cr1</italic><sup>Cre</sup> enabled removal of the lsl (lox-stop-lox) cassette in different tissues of neuronopathic Gaucher disease (nGD) <italic>Cx3cr1</italic><sup>Cre/+</sup> mice.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-79830-fig2-figsupp1-data5-v2.pdf"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata6"><label>Figure 2—figure supplement 1—source data 6.</label><caption><title>Gel image showing <italic>Nes</italic><sup>Cre</sup> enabled removal of the lsl (lox-stop-lox) cassette in brain of neuronopathic Gaucher disease (nGD) <italic>Nes</italic><sup>Cre/+</sup> mice.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-79830-fig2-figsupp1-data6-v2.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Analysis of lipids in neuronopathic Gaucher disease (nGD), nGD <italic>Cx3cr1</italic><sup>Cre/+</sup>, and nGD <italic>Nes</italic><sup>Cre/+</sup> mice brain and behavioral studies.</title><p>(<bold>A</bold>) Fold change increase in different glucosylceramide (GluCer) and glucosylsphingosine (GlcSph) species in nGD, nGD <italic>Cx3cr1</italic><sup>Cre/+</sup>, and nGD <italic>Nes</italic><sup>Cre/+</sup> mice over respective control mice brain. (<bold>B</bold>) Quantitative analysis of total galactosylceramide (GalCer) species and galactosylsphingosine (GalSph) levels by LC-ESI-MS/MS in nGD, nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice, and nGD <italic>Nes</italic><sup>Cre/+</sup> mice brain compared with the control mice (n = 4–8 mice/group). (<bold>C</bold>) Signal intensities of HexCer species (d18:1/20:0) and LysoPC identified by MALDI across nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> and control littermates (<bold>D</bold>) and nGD <italic>Nes</italic><sup>Cre/+</sup> mice and control mice. The color bars in MALDi images show signal intensity: blue to red indicates low to high levels. The data is representative of three independent experiments. (<bold>E</bold>) nGD <italic>Nes</italic><sup>Cre/+</sup> mice showed motor deficits in the balance beam test compared to control mice. (<bold>F</bold>) Representative track plots obtained from open-field studies show circling behavior in nGD <italic>Nes</italic><sup>Cre/+</sup> mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig2-figsupp2-v2.tif"/></fig></fig-group><p>As expected, there was no change in the levels of galactosylceramide (GalCer) species or galactosylsphingosine (GalSph) in nGD brains (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>). MALDI imaging of frozen brain sagittal sections was performed to assess the topography of GSL accumulation. Elevated levels of numerous hexosylceramides (HexCers) were detected in nGD brains. Of these, HexCer (18:1/22:0) exhibited higher signal intensity in the cerebral cortex and midbrain region of nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> brains compared to control mice (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2C</xref>). Similarly, HexCer (18:1/20:0) species was elevated in the same brain regions of nGD <italic>Nes</italic><sup>Cre/+</sup> mice (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2D</xref>). Interestingly, a co-regulated lipid in GD cell models, lysophosphatidylcholine (LysoPC) (<xref ref-type="bibr" rid="bib9">Bodennec et al., 2002</xref>), showed striking accumulation in the cerebral cortex and midbrain region of nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> and nGD <italic>Nes</italic><sup>Cre/+</sup> mice (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2F and G</xref>, lower panel). Assessment of motor balance and coordination showed that the longer-lived adult nGD <italic>Nes</italic><sup>Cre/+</sup> (4–6 months) mice were unable to complete the balance beam runs with an average time &gt;60 s (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2E</xref>). Notably, there were unusual repetitive circling body movements (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2F</xref>). These features appear to phenocopy behavioral disorders reported in human GD3 (<xref ref-type="bibr" rid="bib1">Abdelwahab et al., 2017</xref>). Taken together, these results indicate the differential role of <italic>Gba</italic> in individual cell types in the brain. Notably, reconstituting <italic>Gba</italic> in microglia of nGD mice affords an impressive capacity to offset toxic lipid accumulation in the brain and significantly prolong survival.</p></sec><sec id="s3-3"><title>Selective deletion of <italic>Gba</italic> in microglia results in late-onset neurodegeneration</title><p>To further establish the role of <italic>Gba</italic> in microglia, we used our <italic>Gba</italic> floxed mice (<xref ref-type="bibr" rid="bib37">Mistry et al., 2010</xref>) for microglia-specific <italic>Gba</italic> deletion using <italic>Cx3cr1</italic>-Cre (<xref ref-type="bibr" rid="bib66">Yona et al., 2013</xref>) (<italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup>) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). We investigated this mouse strain for clinical phenotype, brain GluCer/GlcSph accumulation, neuroinflammation, and whether microglia/macrophages underwent compensatory recycling in the setting of microglia-specific <italic>Gba</italic> deficiency. Remarkably, <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> brains showed a pronounced accumulation of GlcSph and several GluCer species (C16, C18, C20, and C22 GluCer species) compared to control brains (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). There was no change in the levels of GalCer or GalSph species (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Young mice appeared healthy despite accumulation of GluCer/GlcSph in the brain, but aged <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> mice (~12 months old) started to exhibit motor deficits manifested by a longer time to complete the beam walk and increased tendency to slip (data not shown). HPLC-MS/MS analysis revealed elevated levels of GlcSph in the sera of young <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> mice (6–8 weeks), which tended to increase further in aged (14 months) mice compared to healthy controls (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Congruently, there was a significant reduction in microglia and increase in CCR2<sup>+</sup> MFs and immune cell infiltration in aged <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> mice, while no changes were observed in young <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> mice (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). We attributed increase of infiltrating CCR2<sup>+</sup> MFs in aged <italic>Gba</italic><sup>fl/lfl</sup> <italic>Cx3cr1</italic><sup>Cre/+</sup> mice brain compared to young mice to higher turnover rate as seen by BrdU uptake assay (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C and D</xref>). In contrast to nGD mice with florid neuroinflammation, we could not detect Pro IL-1ß induction in microglia of <italic>Gba</italic><sup>fl/fl</sup> <italic>Cx3cr1</italic><sup>Cre/+</sup> mice (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1E</xref>). We isolated FACS-sorted microglia from young and aged <italic>Gba</italic><sup>fl/fl</sup> <italic>Cx3cr1</italic><sup>Cre/+</sup> brains to perform scRNA-seq. A total of 2302 microglial cell transcriptomes were subjected to Louvain clustering, resulting in nine transcriptionally distinct microglial states (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). The proportion of individual microglial clusters were differentially enriched in young vs. aged mice brain (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Taking advantage of the single-cell resolution of our data and published microglia-specific lineage genes (<xref ref-type="bibr" rid="bib12">Chen and Colonna, 2021a</xref>; <xref ref-type="bibr" rid="bib13">Chen et al., 2021b</xref>; <xref ref-type="bibr" rid="bib62">Wang et al., 2020</xref>), we identified homeostatic microglial clusters (0, 2, 3, and 6), DAM clusters (1 and 4), a hitherto undescribed <italic>Gba</italic> locus-associated gene cluster (cluster 5, we refer to it as <italic>Gba</italic> cluster because <italic><underline>Mtx1</underline></italic> <underline>and <italic>Thbs3</italic></underline> are contiguous with <italic>the Gba</italic> gene), and ISG cluster (cluster 7) (<xref ref-type="fig" rid="fig3">Figure 3E and F</xref>). In young <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> mice, homeostatic microglia represented by clusters 0, 2, 3, and 6 were the predominant microglia population (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Notably, in aged <italic>Gba</italic><sup>fl/fl</sup> <italic>Cx3cr1</italic><sup>Cre/+</sup> brains, DAM signature clusters (1 and 4), along with <italic>the Gba</italic> locus-associated gene cluster (cluster 5) and interferon-induced gene cluster (cluster 7), represented the major microglial populations (<xref ref-type="fig" rid="fig3">Figure 3F</xref>). Therefore, with aging transition of homeostatic microglia (cluster 2) into DAM microglia cluster with higher expression of DAM genes (<italic>Apoe</italic>, <italic>Spp1</italic>, <italic>Lpl</italic>, <italic>Ccl3</italic>, and <italic>Cst7</italic>) and lower levels of homeostasis genes (<italic>P2ry12</italic> and <italic>Tmem119</italic>) was evident (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Aged <italic>Gba</italic><sup>fl/fl</sup> <italic>Cx3cr1</italic><sup>Cre/+</sup> microglia also expressed higher levels of chemokines (<italic>Ccl3</italic>, <italic>Ccl4</italic>, <italic>Ccl2</italic>, etc.), inflammatory molecules (<italic>Tnf</italic>, <italic>Il1a</italic>, and <italic>Il1b</italic>), and key DAM signature genes (<italic>Apoe</italic>, <italic>Spp1</italic>, <italic>Lpl</italic>, <italic>Ccl3</italic>, and <italic>Cst7</italic>) (<xref ref-type="fig" rid="fig3">Figure 3G</xref>). Notably, CCL2/CCR2 interaction mediates the recruitment of CCR2-bearing leukocytes in the brain in several neuroinflammatory diseases (<xref ref-type="bibr" rid="bib35">Mahad et al., 2006</xref>). In this context, aged <italic>Gba</italic><sup>fl/fl</sup> <italic>Cx3cr1</italic><sup>Cre/+</sup> mice microglia displaying higher expression of Ccl2 and other inflammatory chemokine<italic>s</italic> may mediate infiltration of peripheral CCR2<sup>+</sup> MFs and leukocytes contributing to neuroinflammation seen in our late-onset neurodegeneration model, akin to that seen in some GD1 patients with aging (<xref ref-type="bibr" rid="bib6">Belarbi et al., 2020</xref>). Interestingly, expression of <italic>Mtx1</italic> and <italic>Thbs3</italic> genes that are assigned to chromosome 1q21 contiguous with <italic>Gba</italic> was enriched in cluster 5 and prominent in aged<italic>Gba<sup>fl/fl</sup>Cx3cr1</italic> microglia (we have termed these <italic>Gba</italic>-associated genes). The expression of IFN response genes in microglia cluster 7 remained unchanged between young and aged mice (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Taken together, molecular elucidation of aged <italic>Gba-</italic>deficient microglia shows a loss of homeostatic signature with pronounced expression of inflammatory signaling molecules. Thus, our findings highlight the important role of <italic>Gba</italic> in long-term maintenance of microglial homeostasis and implicates <italic>GBA</italic> deficient microglia in the development of age-related neurodegenerative disease like PD that occurs with high risk in adults with GD1.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Aged <italic>Gba</italic><sup>fl/fl</sup><italic>Cx3cr1</italic><sup>Cre/+</sup> mice brain show alteration of microglia subsets and neurodegeneration.</title><p>(<bold>A</bold>) Quantitative analysis of total glucosylceramide/glucosylsphingosine (GluCer/GlcSph) levels in <italic>Gba</italic><sup>fl/fl</sup><italic>Cx3cr1</italic><sup>Cre/wt</sup> mice and control mice (n = 3 mice/group). Statistical significance was determined using <italic>t</italic>-test using Bonferroni–Dunn correction for multiple comparisons (*p&lt;0.05, **p&lt;0.001, and ***p&lt;0.0001). (<bold>B</bold>) Quantitative analysis of serum GlcSph levels in young and aged <italic>Gba</italic><sup>fl/fl</sup><italic>Cx3cr1</italic><sup>Cre/wt</sup> mice and control mice (n = 8–11 mice/group; repeated at least three times). (<bold>C</bold>) Bar graph shows comparison of percentage of CCR2<sup>+</sup> MFs, microglia, and immune infiltrates between young and aged <italic>Gba</italic><sup>fl/fl</sup><italic>Cx3cr1</italic><sup>Cre/wt</sup> mice and control mice (n = 3 mice/group; repeated at least three times). (<bold>D</bold>) UMAP plots show clustering of microglia from young and aged <italic>Gba</italic><sup>fl/fl</sup><italic>Cx3cr1</italic><sup>Cre/wt</sup> mice. Cells are colored by cluster (left) and age (right). (<bold>E</bold>) Hierarchical heat map depicting differential expression of gene<italic>s</italic> taken from Wang et al. and compared between microglia cluster from young and aged <italic>Gba</italic><sup>fl/fl</sup><italic>Cx3cr1</italic><sup>Cre/wt</sup> mice. (<bold>F</bold>) Fraction of cells for each cluster present in young and aged <italic>Gba</italic><sup>fl/fl</sup><italic>Cx3cr1</italic><sup>Cre/wt</sup> mice, respectively. (<bold>G</bold>) Gene expression heat map for clusters defined as microglia. (<bold>A, B</bold>) Data represents three biological replicates. Means ± SEM are shown. Unpaired <italic>t</italic>-test, two-tailed was used to test significance *p&lt;0.05, **p&lt;0.001, and ***p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Changes in microglia subsets coupled with neurodegeneration are seen in aged Gba<sup>fl/fl</sup> <italic>Cx3cr1</italic><sup>Cre/+</sup> mice brain.</title><p>(<bold>A</bold>) Genotyping for <italic>Cx3cr1</italic> <sup>cre</sup> and loxp alleles. (<bold>B</bold>) Quantitative analysis of total galactosylceramide (GalCer) species and galactosylsphingosine (GalSph) levels by LC-ESI-MS/MS in Gba<sup>fl/fl</sup> <italic>Cx3cr1</italic><sup>Cre/+</sup> mice brain compared with the control mice (n = 4–8 mice/group). (<bold>C</bold>) Representative plots depicting BrdU incorporation in the microglia, CCR2<sup>+</sup> MFs and immune infiltrates isolated from Gba<sup>fl/fl</sup> <italic>Cx3cr1</italic><sup>Cre/+</sup> and control mice brain. (<bold>D</bold>) Comparison of percentage of BrdU + microglia, CCR2<sup>+</sup> MFs, and immune infiltrates between Gba<sup>fl/fl</sup> <italic>Cx3cr1</italic><sup>Cre/wt</sup> and control mice brain (n = 3 mice/group). (<bold>E</bold>) Percentage of Pro-IL-1ß<sup>+</sup> microglia cells in control and Gba<sup>fl/fl</sup> <italic>Cx3cr1</italic><sup>Cre/+</sup> mice (n = 5–6 mice/group). Data represents three biological replicates. Means ± SEM are shown. Unpaired <italic>t</italic>-test, two-tailed was used to test significance *p&lt;0.05, **p&lt;0.001, and ***p&lt;0.0001.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Gel image showing genotype of Gba<sup><italic>fl/fl</italic></sup> <italic>Cx3cr1</italic><sup>Cre/+</sup> mice having conditional deletion of the Gba gene through <italic>Cx3cr1</italic><sup>Cre</sup> expression.</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="elife-79830-fig3-figsupp1-data1-v2.pdf"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig3-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s3-4"><title>NK cells, together with microglial activation, drive neuropathology in nGD brains</title><p>Analysis of immune cell infiltrates by scRNA-seq in the brains of nGD and nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice revealed significant infiltration of NK cells (Fig. S1B and E). We confirmed striking NK infiltration in nGD brains by flow cytometry (<xref ref-type="fig" rid="fig4">Figure 4A–C</xref>). Brain-infiltrating NK cells expressed granzyme A (GzmA) (<xref ref-type="fig" rid="fig4">Figure 4D–F</xref>). Interestingly, higher percentages of NK cell infiltration were observed in nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice brain compared to nGD mice brain. It should be noted that there is increased attrition/death of microglia in nGD mice compared to nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice. Taking these observations into consideration, we surmise that inflammatory cytokines and chemokines secreted by activated microglia that are present in higher proportion in nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice induce robust NK cell infiltration into brains than seen in nGD mice. NK cell frequency and GzmA expression were unaltered in the spleens of both nGD and nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>, <xref ref-type="fig" rid="fig4">Figure 4G and H</xref>), implying that the primary cues responsible for activation of NK cells were emanating from within the nGD brains. Sphingosine 1-phosphate (Sph-1P) plays a key role in NK cell trafficking via its receptor S1P5 (<xref ref-type="bibr" rid="bib61">Walzer et al., 2007</xref>). To address whether Sph-1P is involved in NK cell infiltration in nGD brain, we performed HPLC-MS/MS analysis of brain tissue for sphingosine species. We found no specific buildup of sphingosine lipid species including Sph-1P in nGD and nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice brains compared to the control mice (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>), suggesting that other mechanism(s) may underlie NK cell infiltration or that there is local generation of S1P that is beyond the resolution of HPLC-MS/MS.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>NK cell infiltration into the brain of neuronopathic Gaucher disease (nGD), nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice.</title><p>(<bold>A</bold>) CD45<sup>+</sup> cells form the whole brain of nGD, nGD <italic>Cx3cr1</italic><sup>Cre/+</sup>, and control mice were gated to analyze CD3<sup>-</sup>NK1.1<sup>+</sup> NK cells. Bar graphs represent the percentage of NK cells in the immune infiltrates of (<bold>B</bold>) nGD mice brain (n = 5mice/group) and (<bold>C</bold>) nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice brain, respectively (n = 4 mice/group). (<bold>D</bold>) Expression of granzyme A (GzmA) in the brain infiltrating NK cells of nGD and nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice. Bar graphs compare the percentage of GzmA<sup>+</sup> NK cells in in the immune infiltrates of (<bold>E</bold>) nGD vs. control mice brain (n = 5 mice/group) and (<bold>F</bold>) nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> vs. control mice brain, respectively (n = 4 mice/group). Percentage of NK1.1<sup>+</sup> NK cells and GzmA<sup>+</sup> NK cells in the spleen of (<bold>G</bold>) nGD mice and (<bold>H</bold>) nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice (n = 4–5 mice/group). Bar graph showing percentage of (<bold>I</bold>) immune infiltrates (<bold>J</bold>) Pro-IL-1ß<sup>+</sup> microglia cells (<bold>K</bold>) percentage of NK cells and (<bold>L</bold>) GzmA<sup>+</sup> NK cells in the whole brain of <italic>Gba</italic><sup>wt/wt</sup> treated with vehicle or conduritol β-epoxide (CBE). Experiments were repeated thrice. (<bold>A</bold>) and (<bold>D</bold>) were representative from one of the experiments, (<bold>B</bold>), (<bold>C</bold>), (<bold>E–L</bold>) Data are combined from two such experiments. Data are shown as means ± SEM. Unpaired <italic>t</italic>-test, two-tailed was used to test significance. *p&lt;0.05, **p&lt;0.001, and ***p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>NK cell infiltration into the brain of neuronopathic Gaucher disease (nGD), nGD Cx3cr1<sup>Cre/+</sup> mice.</title><p>(<bold>A</bold>) Representative fluorescence-activated cell sorting (FACS) plot showing NK1.1<sup>+</sup> NK cells and Gzm-A<sup>+</sup> NK cells in the spleen of nGD, nGD <italic>Cx3cr1</italic><sup>Cre/+</sup>, and control littermates. (<bold>B</bold>) Lipidomic analysis by LC-MS/MS of sphingosine-1-phosphate (S1P) and sphingosine (Sph) content in brains from nGD, nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice, and control littermates (n = 3mice/group). (<bold>C</bold>) Representative FACS plot showing percentage of immune infiltrates (top panel), NK1.1<sup>+</sup> NK cells (middle panel), and GzmA<sup>+</sup> NK cells (bottom panel) in B6 treated with vehicle or conduritol β-epoxide (CBE).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig4-figsupp1-v2.tif"/></fig></fig-group><p>To assess whether the pattern of neuroinflammation observed in genetic models of nGD could be replicated in another system, we used a chemically induced model of nGD using an inhibitor of acid β-glucosidase (CBE). Administration of CBE in WT mice resulted in the nGD phenotype, as described previously (<xref ref-type="bibr" rid="bib21">Farfel-Becker et al., 2011</xref>; <xref ref-type="bibr" rid="bib29">Kanfer et al., 1982</xref>). FACS analysis of immune cells in the brains of CBE-treated mice revealed major infiltration of immune cells (<xref ref-type="fig" rid="fig4">Figure 4I</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>) as well as Pro-IL-1ß induction in the microglia (<xref ref-type="fig" rid="fig4">Figure 4J</xref>). Like genetic models, immune cell phenotyping in the brains of CBE-treated mice showed striking induction of GzmA<sup>+</sup> NK cells (<xref ref-type="fig" rid="fig4">Figure 4K and L</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>). Therefore, using genetic and chemically induced nGD mouse models, we confirmed a conserved immune landscape of nGD brains comprising prominent NK cell infiltration and microglial activation.</p></sec><sec id="s3-5"><title>Single-cell resolution revealed role of microglial <italic>Gba</italic> in delaying neuroinflammation</title><p>To gain a comprehensive and dynamic overview of the underlying mechanisms involved in the longitudinal course of GD-associated neurodegeneration, we performed brain single-nucleus RNA-seq to elucidate cell types/pathways in three experimental settings: (1) the acute neuropathic model nGD mice at 2 weeks, (2) after restoration of <italic>Gba</italic> in microglia (nGD <italic>Cx3cr1</italic><sup>Cre/+</sup>) at early asymptomatic stage (2 weeks) and late stage (6 weeks) when it displays overt neurodegenerative phenotype, and (3) late-onset model, nGD <italic>Nes</italic><sup>Cre/+</sup> brains with rescue of <italic>Gba</italic> in neuronal compartment (age ~7 months). Integrated hierarchical analysis with quality controls (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>) revealed 61 distinct cell clusters that were annotated for major cell types based on the differential expression of canonical marker genes (<xref ref-type="fig" rid="fig5">Figure 5A</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). We focused on four distinct gene sets: lysosomal biology, ISGs, chemokines, and ApoE. Lipid metabolism genes are known to be upregulated in DAMs. We focused on ApoE because of its established roles in both lipid transport and neurodegeneration highlighted by GD (<xref ref-type="bibr" rid="bib50">Serrano-Pozo et al., 2021</xref>). AUCell analysis was applied to interrogate these gene set enrichments and stratify different cell types: lysosomal biology (<italic>Abca2</italic>, <italic>Ap1b1</italic>, <italic>Ap3s1</italic>, <italic>Ap4s1</italic>, <italic>Atp6v0a1</italic>, <italic>Atp6v1h</italic>, <italic>Cd63</italic>, <italic>Cd68</italic>, <italic>Cln3</italic>, <italic>Ctsb</italic>, <italic>Ctsd</italic>, <italic>Ctsl</italic>, <italic>Ctss</italic>, <italic>Galc</italic>, <italic>Galns</italic>, <italic>Hexa</italic>, <italic>Hexb</italic>, <italic>Lamp</italic>, <italic>Psap</italic>, <italic>Slc17a5</italic>, <italic>Sumf1</italic>, <italic>Gpr37</italic>, <italic>Gpr37l1</italic>, <italic>Mtx1,</italic> and <italic>Thbs3</italic>); interferon signaling genes (<italic>Psmb10</italic>, <italic>Psmb9</italic>, <italic>Psmb8</italic>, <italic>Psma4</italic>, <italic>Psme2</italic>, <italic>Oas1a</italic>, <italic>Oasl2</italic>, <italic>Oasl1</italic>, <italic>Isg15</italic>, <italic>Ifi207</italic>, <italic>Ifi47</italic>, <italic>Ifit1</italic>, <italic>Ifi213, Ifitm3</italic>, <italic>Ifit3</italic>, <italic>Ifi35</italic>, <italic>Epsti1</italic>, <italic>Parp14</italic>, <italic>Bst2</italic>, <italic>Irf7</italic>, <italic>Irf9</italic>, <italic>Stat1</italic>, <italic>Stat2</italic>, <italic>Usp18</italic>, <italic>Ifit2</italic>, <italic>Slfn5,</italic> and <italic>Ifih1</italic>); chemokine genes (<italic>Cxcl10</italic>, <italic>Cxcl12</italic>, <italic>Ccl5</italic>, <italic>Cxcl5</italic>, <italic>Ccl2</italic>, <italic>Ccl3,</italic> and <italic>Ccl7</italic>); and ApoE. In the brains of nGD and 6-week-old nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice both with overt neurodegenerative phenotypes, lysosomal biology, ISG, and ApoE genes were highly upregulated in microglia, Purkinje, oligodendrocytes (clusters 2, 34, and 36), astrocytes (clusters 22, 23, 4, 48, 52, and 9), and neurons (0, 3, 5, and 6) (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). In contrast, microglia of 2-week-old nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice were similar to controls. In line with these observations, DAM markers were significantly enriched in microglia from both nGD and 6-week-old nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> compared to 2-week-old nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C</xref>), consolidating the importance of microglial <italic>Gba</italic> in ameliorating neurodegeneration seen in florid acute neuroinflammation. Importantly, the results suggest that even in setting of normal microglia <italic>Gba</italic> in nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice, increased flux of glucosylceramide lipids arising from <italic>Gba</italic>-deficient neuronal cells leads to DAM over time as seen at 6 weeks but not at 2 weeks in these mice. <italic>Gba</italic> rescue in the neuronal compartment resulted in the normalization of pathways associated with lysosomal biology genes, ISG genes, chemokine genes, and ApoE in microglia, Purkinje, oligodendrocytes, astrocytes, and neuron cell clusters, and in other brain cell clusters (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Nevertheless, lower expression of homeostatic microglia markers was observed in nGD <italic>Nes</italic><sup>Cre/+</sup> microglia compared to control mice (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1D</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>snRNA-seq reveals key role of microglia astrocytes and neurons in Gaucher disease (GD)-associated neuroinflammation.</title><p>(<bold>A</bold>) UMAP data from neuronopathic Gaucher disease (nGD) (2 weeks old), nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> (2 and 6 weeks old, respectively), nGD <italic>Nes</italic><sup>Cre/+</sup> mice (n = 3), and corresponding control mice, colored by genotype (top) and cell clusters (bottom). (<bold>B</bold>) AUC analysis for select lysosome, Interferon signature genes (ISG), chemokine, and Apoe gene sets significantly enriched (false discovery rate [FDR] &lt; 0.05) in microglia, Purkinje, oligodendrocyte, astrocyte, and neuro clusters of nGD (2 weeks) vs. control mice; nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> (2 and 6 weeks, respectively) vs. control mice; nGD <italic>Nes</italic><sup>Cre/+</sup> mice vs. control mice. Row side bar colors indicate mice genotype, age and cell clusters. (<bold>C</bold>) Pie chart displays the number of differentially expressed genes (DEGs) in neuronal clusters of nGD (2 weeks) vs. control mice (green); nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> (2 weeks [orange] and 6 weeks [maroon], respectively); nGD <italic>Nes</italic><sup>Cre/+</sup> mice (pink) vs. control mice with log2(fold change) and adjusted p-value &lt; 0.05. Total DEGs from each set of mice are stated in the middle of pie chart with number of DEGs and the neuronal cluster in brackets shown to the right of each pie chart. (<bold>D</bold>) Bar graph represents the number of DEGs in neuronal clusters of nGD 2 weeks (green) vs. nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> 6 weeks (maroon) with log2(fold change) and adjusted p-value &lt; 0.05. (<bold>E</bold>) Heat map of DEGs associated with disease-associated astrocytes (DAA) from nGD; nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> (2 weeks and 6 weeks, respectively); nGD <italic>Nes</italic><sup>Cre/+</sup> mice vs. control mice. p&lt;0.05 was considered significant (two-sided <italic>t</italic>-tests). All individual DAA genes with significant differential expression are listed on bottom and the astrocyte clusters are shown in right. Red, positive z-score; white, zero z-score; blue, negative z-score. (<bold>F</bold>) Ingenuity pathway analysis (IPA) from nGD vs. WT, nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> vs. WT <italic>Cx3cr1</italic><sup>Cre/+</sup> at 2- and 6-week-old mice; nGD <italic>Nes</italic><sup>Cre/+</sup> mice vs. WT <italic>Nes</italic><sup>Cre/+</sup> in neuron cluster, microglia, and astrocytes. Orange, positive z-score; white, zero z-score; blue, negative z-score; gray dots are statistically insignificant. (<bold>G</bold>) Representative flow cytometry histogram (left) and quantification of CellROX fluorescence in astrocytes. (<bold>H</bold>) Histogram (left) and quantification (right) of BODIPY fluorescence in astrocytes of nGD mice. (<bold>I</bold>) Flow cytometry histogram (left) and quantification (right) of CellROX fluorescence in activated and homeostatic microglia from nGD mice. (<bold>J</bold>) Histogram (left) and quantification (right) of BODIPY fluorescence in activated and homeostatic microglia from nGD mice n = 3–4 mice per group. Data were replicated in at least two independent experiments. Unpaired <italic>t-</italic>test, two-tailed was used to test significance. *p&lt;0.05, **p&lt;0.001, and ***p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>snRNA-seq analysis of the brain of neuronopathic Gaucher disease (nGD), nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice.</title><p>(<bold>A</bold>) Analysis of snRNA-seq data of nGD (green), <italic>Gba</italic><sup>wt/lwt</sup> (blue), nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> 2 and 6 weeks old (maroon), <italic>Gba</italic><sup>wt/wt</sup><italic>Cx3cr1</italic><sup>Cre/+</sup> 2 and 6 weeks old (black), nGD <italic>Nes</italic><sup>Cre/+</sup> mice (pink) (n = 3), and <italic>Gba</italic><sup>wt/wt</sup> <italic>Nes</italic><sup>Cre/+</sup> (gray) (n = 3). Violin plots showing the total number of detected genes (nFeature), reads counts (nCount), proportion of mitochondria (percent.mt) contamination per nucleus for each sample. (<bold>B</bold>) Violin plots showing the cluster-specific expression of the canonical marker genes across all clusters. (<bold>C</bold>) Dot plot showing the differential expression of homeostatic and disease-associated microglial (DAM) genes (dotted box) in microglia from nGD, <italic>Gba</italic><sup>wt/lwt</sup>, nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> 2 and 6 weeks old, <italic>Gba</italic><sup>wt/wt</sup><italic>Cx3cr1</italic><sup>Cre/+</sup> 2 and 6 weeks old, nGD <italic>Nes</italic><sup>Cre/+</sup> mice (n = 3), and <italic>Gba</italic><sup>wt/wt</sup> <italic>Nes</italic><sup>Cre/+</sup> (n = 3), respectively. (<bold>D</bold>) Dot plot showing the differential expression of homeostatic (dotted box) and DAM genes in microglia from nGD Nes<sup>Cre/+</sup> mice (n = 3) and Gba<sup>wt/wt</sup> <italic>Nes</italic><sup>Cre/+</sup> (n = 3), respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig5-figsupp1-v2.tif"/></fig></fig-group><p>Gene expression analysis revealed that nGD mice exhibited the largest number of differentially expressed genes (DEGs) (n = 19,274), which were strikingly reduced in 2-week-old nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> (n = 125) and also in nGD <italic>Nes</italic><sup>Cre/+</sup> brains, n = 256 (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Consistent with the neuroinflammation observed in 6-week-old nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice, elevated DEGs in neuronal clusters were seen (n = 7539) compared to 2-week-old nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice (n = 125) (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). However, 6-week-old nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice show a reduction of DEGs in different neuronal clusters compared to nGD mice (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Collectively, these results indicate the underlying role of microglial <italic>Gba</italic> in safeguarding and delaying neuroinflammatory gene networks in nGD brains.</p><p>We found evidence of significant activation of several disease pathways in astrocytes (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). Astrocytosis has been described in immunohistochemistry of mouse and human neuronopathic brains (<xref ref-type="bibr" rid="bib65">Wong et al., 2004</xref>). We analyzed the astrocyte compartment for the disease-associated astrocyte (DAA) gene signature (<xref ref-type="bibr" rid="bib5">Batiuk et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">Habib et al., 2020</xref>). DAA genes were highly induced in astrocyte clusters from nGD mice and in 6-week-old nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice but not in 2-week-old nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). IPA was performed on neurons, astrocytes, and microglia. IPA revealed enrichment of necroptosis, interferon, IL8, TREM1, and neuroinflammation signaling pathways in 2-week-old nGD mice compared to the controls. <italic>Gba</italic> rescue in microglia of 2-week-old nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice showed abrogation of neuroinflammatory pathways seen in nGD brains (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Between 2 and 6 weeks, as neurodegeneration advanced in nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice, the enrichment of inflammatory pathways was again evident (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Notably, both interferon and NK cell signaling pathways were upregulated in 2-week-old nGD and in 6-week-old nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> brains (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Consistent with the lack of microglial activation and NK infiltration in nGD <italic>Nes</italic><sup>Cre/+</sup> mice, IPA revealed no changes in neurons, astrocytes, and microglia in nGD <italic>Nes</italic><sup>Cre/+</sup> mice (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Pathway analysis of differentially expressed genes revealed that the ‘production of nitric oxide and ROS’ was elevated in nGD and 6-week-old nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> microglia and astrocytes along with neuroinflammation pathways. Elevated and dysregulated reactive oxygen species (ROS) production from DAM contributes to oxidative stress and has been shown to be intricately linked with neurodegeneration (<xref ref-type="bibr" rid="bib36">Mendiola et al., 2020</xref>; <xref ref-type="bibr" rid="bib56">Takizawa et al., 2011</xref>). Consistent with the transcriptional changes observed in nGD mice, astrocytes from nGD mice showed higher fluorescence after treatment with CellROX, indicating a higher level of ROS, compared to astrocytes from control mice (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). nGD astrocytes with high ROS level also showed elevated accumulation of neutral lipids, as seen by BODIPY staining (<xref ref-type="fig" rid="fig5">Figure 5H</xref>). Moreover, activated microglia in the nGD brain showed enhanced ROS level along with an increased accumulation of lipids compared to homeostatic microglia (<xref ref-type="fig" rid="fig5">Figure 5I and J</xref>). Overall, these observations suggest that <italic>Gba-</italic>deficient neurons and microglia, laden with GlcCer and GlcSph, play key roles in orchestrating neuroinflammation involving astrocytes and NK cells that underlie neurodegeneration in neuronopathic GD.</p></sec><sec id="s3-6"><title>GCS inhibitor reduces GluCer/GlcSph and reverses microglia and NK cell activation</title><p>Collectively our findings suggest that lipid dyshomeostasis and neurodegeneration caused by <italic>Gba</italic> deficiency in microglia and neurons can be prevented by restoration of <italic>Gba</italic>. Previous studies have shown that treatment with GCS inhibitor GZ-161 reduced GluCer and GlcSph in the brains of nGD mice and prolonged survival by a few days (<xref ref-type="bibr" rid="bib11">Cabrera-Salazar et al., 2012</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). To determine whether reduction of glucosylceramide lipids by GZ-161 alleviates neuroinflammatory landscape and neurodegeneration, we treated our mouse models with this brain-permeant GCS inhibitor. Consistent with previous studies, GZ-161 treatment significantly prolonged the survival of nGD mice (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). We investigated whether GZ-161 treatment could further extend the survival of nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice by more effective reduction of brain GluCer/GlcSph via dual effects of decreased synthesis of GluCer and increased lysosomal degradation of GluCer. Indeed, GZ-161 treatment of nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice resulted in considerable extension of survival compared to untreated mice, with analogous normalization of GlcSph levels in the sera of treated nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice (<xref ref-type="fig" rid="fig6">Figure 6A and B</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Effects of glucosylceramide synthase (GCS) inhibitor (GZ-161) on microglia and GzmA<sup>+</sup> cells.</title><p>(<bold>A</bold>) Kaplan–Meier survival analysis of neuronopathic Gaucher disease (nGD) and nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice after GZ-161 treatment compared to vehicle-treated controls (n = 4–10 mice/group). (<bold>B</bold>) Quantitative analysis of serum glucosylsphingosine (GlcSph) levels by LC-ESI-MS/MS in nGD, nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice with and without GZ-161 treatment compared with the vehicle-treated controls (n = 4–10 mice/group). (<bold>C</bold>) Representative fluorescence-activated cell sorting (FACS) staining of microglia, activated microglia, and immune infiltrates in wild-type and nGD mice with and without treatment with GZ-161. (<bold>D</bold>) Graph represents percentages of microglia, CCR2<sup>+</sup> MFs and immune infiltrates in wild-type and nGD mice with and without treatment with GZ-161 (n = 4–6 mice/group). (<bold>E</bold>) Bar graph showing percentage of Pro-IL-1ß<sup>+</sup> microglia cells in wild-type and nGD mice with and without treatment with GZ-161 (n = 3–5 mice/group; repeated at least three times). (<bold>F</bold>) Bar graph showing percentage of Pro-IL-1ß<sup>+</sup> microglia cells in wild-type and nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice with and without treatment with GZ-161 (n = 3–5 mice/group). (<bold>G</bold>) Percentage of GzmA<sup>+</sup> CD45<sup>+</sup> cells in wild-type and nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice with and without treatment with GZ-161 (n = 3–5 mice/group). (<bold>H</bold>) Bar graphs compare the percentage of NK cells in <italic>Gba</italic><sup>wt/wt</sup> and mice treated with conduritol β-epoxide (CBE) and CBE + GZ-161, respectively (n = 3–5 mice/group; repeated at least three times). Data represents three biological replicates. Means ± SEM are shown. Unpaired <italic>t</italic>-test, two-tailed was used to test significance. *p&lt;0.05, **p&lt;0.001, and ***p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Immune regulatory effects of glucosyl ceramide synthetase (GCS) inhibitor GZ-161 on microglia and GzmA<sup>+</sup> cells.</title><p>(<bold>A</bold>) Schematic illustration of mode of action of GCS inhibitor. (<bold>B</bold>) Representative fluorescence-activated cell sorting (FACS) plot showing percentage of Pro-IL-1ß<sup>+</sup> microglia cells (left) and GzmA<sup>+</sup> CD45<sup>+</sup> (right) in wild-type and neuronopathic Gaucher disease (nGD) <italic>Cx3cr1</italic><sup>Cre/+</sup>mice with and without treatment with GZ-161.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig6-figsupp1-v2.tif"/></fig></fig-group><p>Next, we assessed the impact of pharmacological reduction of GluCer/GlcSph on disease-specific, microglial and macrophage phenotypes associated with neuroinflammation in GD mice models. FACS analysis of GZ-161-treated nGD mice showed that the GCS inhibitor significantly reduced the proportion of CCR2<sup>+</sup> MFs, concomitantly with restoration of homeostatic microglia compartment (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>). However, GZ-161 treatment had no effect on immune cell infiltrates in the brains of nGD mice (<xref ref-type="fig" rid="fig6">Figure 6C and D</xref>). GZ-161 treatment showed a nonsignificant downward trend in microglial Pro-IL-1ß induction in nGD mice (<xref ref-type="fig" rid="fig6">Figure 6E</xref>). GZ-161 treatment in longer-lived nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice wherein drug administration was more reliable resulted in significantly increased survival (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) accompanied by a reduction in Pro-IL-1ß<sup>+</sup> microglia as well as a reduction in GzmA<sup>+</sup> immune cells in the brain (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>, <xref ref-type="fig" rid="fig6">Figure 6F and G</xref>). We further evaluated the ability of GZ-161 to counteract NK cell induction seen in the CBE model. Administration of GZ-161 in CBE-treated mice reduced infiltration of NK cells in the brain (<xref ref-type="fig" rid="fig6">Figure 6H</xref>). Together, these results show that GZ-161 can mitigate the metabolic defect caused by <italic>Gba</italic> deficiency by reducing the accumulation of GluCer and GlcSph, concurrent with alleviating CNS immune inflammation involving microglia and NK cell activation. Moreover, when microglia are predominantly of homeostatic phenotype through complementation of <italic>Gba</italic> function in nGD mice, a two-pronged approach of restoring <italic>Gba</italic> in microglia and GCS inhibitor, the influx of NK cells into the brain and subsequent neurodegeneration is significantly constrained.</p></sec><sec id="s3-7"><title>GCS inhibition counteracts age-related microglial dysfunction and NK cell activation</title><p>We investigated whether buildup of GlcCer and GlcSph is proximate cause of neuroinflammation and neurodegeneration in <italic>Gba</italic> deficiency using the brain-permeant GCS inhibitor in late-onset neurodegeneration <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> model. The effect of reversing the toxic accumulation of GluCer/GlcSph on in vivo microglial homeostasis and NK cell activation was assessed by feeding <italic>Gba<sup>fl/fl</sup></italic> control mice and <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> mice with either control or GZ-161-formulated diet, starting at age 3 months, for 7 months. The effect of GZ-161 on GSL accumulation in brain regions was evaluated using MALDI imaging. <italic>Gba</italic><sup>fl/fl</sup><italic>Cx3cr1</italic><sup>Cre/+</sup> mice accumulated HexCer (d18:1/18:0) and HexCer (d18:1/20:0) in the corpus callosum (<xref ref-type="fig" rid="fig7">Figure 7A</xref>), which was normalized upon GZ-161 diet. Concomitantly, there was a reduction in HexCer (18:1/22:0) accumulation in the cerebral cortex (<xref ref-type="fig" rid="fig7">Figure 7A</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Long-term treatment with glucosylceramide synthase (GCS) inhibitor, GZ-161, counteracts age-related microglial dysfunction and NK cell activation.</title><p>(<bold>A</bold>) Signal intensities of hexosylceramides (HexCer) species and lysophosphatidylcholine (LysoPC) identified by MALDI across <italic>Gba</italic><sup>fl/fl</sup><italic>Cx3cr1</italic><sup>Cre/wt</sup> mice treated with either vehicle or GZ161 and control mice brain. The color bars in MALDI images show signal intensity: blue to yellow indicates low to high levels. (<bold>B</bold>) UMAP plots show clusters of CD45<sup>+</sup> cells from brain of control and <italic>Gba</italic><sup>fl/fl</sup><italic>Cx3cr1</italic><sup>Cre/wt</sup> mice treated with either GZ161 or vehicle. Cells are colored by mice genotype (left top) and cluster (left bottom). Microglia subcluster of CD45<sup>+</sup> cells, colored by mice (right top) and clusters (right bottom). (<bold>D</bold>) Hierarchical heat map depicting differential expression of genes associated with homeostatic and disease-associated microglia in the different microglia clusters. (<bold>D</bold>) Fraction of cells present in each microglial cluster from control and <italic>Gba</italic><sup>fl/fl</sup><italic>Cx3cr1</italic><sup>Cre/wt</sup> mice treated with either GZ161 or vehicle. (<bold>E</bold>) Histogram showing differential expression of selected genes in cluster 17 from control and <italic>Gba</italic><sup>fl/fl</sup><italic>Cx3cr1</italic><sup>Cre/wt</sup> mice treated with either GZ161 or vehicle.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Long-term treatment with glucosylceramide synthase (GCS) inhibitor, GZ-161, counteracts glucosylceramide (GluCer) accumulation, improves microglial homeostasis, and abrogates NK cell activation in <italic>Gba</italic>-deficient microglia.</title><p>UMAP showing GzmA expression in the clusters from control and <italic>Gba</italic><sup>fl/fl</sup> <italic>Cx3cr1</italic><sup>Cre/wt</sup> mice treated with either vehicle or GZ161.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig7-figsupp1-v2.tif"/></fig></fig-group><p>We performed scRNA-seq of CD45<sup>+</sup> cells from brains of <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> mice and control mice on control or GZ-161-formulated diet. A total of 40,763 CD45<sup>+</sup> single-cell transcriptomes were subjected to unsupervised Louvain clustering resulting in a total of 28 transcriptionally distinct populations comprising 10 broad cell types (<xref ref-type="fig" rid="fig7">Figure 7B</xref>). Clusters 1, 26, and 16 represented microglia (4230 cells) and were visualized on UMAP, revealing 15 unique clusters (<xref ref-type="fig" rid="fig7">Figure 7B</xref>, lower panel). We identified clusters 0, 1, and 5 as homeostatic microglia, cluster 2 as DAM, and cluster 7 as <italic>Gba</italic>-associated microglia (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). DAM cluster 2, which was significantly enriched in <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> brains, was markedly reduced in <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> mice fed with GZ-161 diet with concurrent enhancement of homeostatic microglia clusters 0 and 1 (<xref ref-type="fig" rid="fig7">Figure 7D</xref>). We found that <italic>Gba-associated</italic> gene cluster 7 was present exclusively in <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> mice both on GZ-161 and on the control diet groups. To assess the effect of GZ-161 on NK cells within the brain environment, we further analyzed cluster 17, which represented NK cells (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). GZ-161 treatment resulted in reduction of <italic>Gzma</italic>, <italic>Ccl5</italic>, <italic>Tyrobp</italic>, and <italic>Klf2</italic>, with no change in <italic>Klrd1, Klrk1, CD52</italic>, and <italic>Ccl4</italic> (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). Collectively, these results demonstrate that GCS inhibitor-mediated reduction of GluCer and GlcSph counteracts age-related microglial dysfunction and NK cell activation in several brain regions in <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> mice. Together, these findings not only validate GlcCer/GlcSph as the proximate cause of neuroinflammation involving microglia and NK cells but also point to the potential of brain permeant small-molecule inhibitor as a therapeutic approach for neuronopathic GD.</p></sec><sec id="s3-8"><title>Generating novel candidate biomarkers of neurodegeneration in <italic>Gba</italic> deficiency</title><p>Given the striking relationship between serum Nf-L, level of pathogenic lipid, GlcSph, and neurodegenerative phenotype, we sought to validate these biomarkers in translational studies in GD patients and explore other potential biomarkers suggested by our results. Lack of circulating biomarkers for pre-symptomatic <italic>Gba</italic> deficiency-associated neurodegenerative diseases is a major impediment to optimal management of patients and conduct of clinical trials. Therefore, we investigated whether serum levels of neurofilament light (Nf-L), an accepted biomarker of neuroaxonal injury in several neurodegenerative and neuroinflammatory diseases (<xref ref-type="bibr" rid="bib23">Gaetani et al., 2019</xref>; <xref ref-type="bibr" rid="bib31">Khalil et al., 2020</xref>; <xref ref-type="bibr" rid="bib34">Loeffler et al., 2020</xref>; <xref ref-type="bibr" rid="bib63">Weinhofer et al., 2021</xref>), could serve as a biomarker of neurodegeneration in nGD models. Using ultra-sensitive Quanterix Simoa, we found a massive 2000-fold elevation of serum Nf-L in nGD mice, ~100-fold elevation in nGD <italic>Cx3cr1</italic><sup>Cre/+</sup>, and ~20-fold elevation in nGD <italic>Nes</italic><sup>Cre/+</sup> mice (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). Remarkably, GZ-161 treatment, which led to reductions in GlcSph levels, also led to a significant decline in serum Nf-L levels in nGD and nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). Serum Nf-L level in nGD mice (18,100 ± 4809 pg/ml) was reduced by GZ-161 treatment to 6876 ± 1080 pg/ml. Conversely, GZ-161 treatment of nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice dramatically reduced Nf-L level to 1297 ± 534.1 pg/ml compared to untreated mice (5466 ± 557.2 pg/ml). The residual Nf-L level after GZ-161 treatment in nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice was significantly lower than that in nGD mice treated with GZ-161, consistent with the synergistic effect of GCS inhibition and restoration of <italic>Gba</italic> function in microglia (<xref ref-type="fig" rid="fig8">Figure 8A</xref>). Increased survival of nGD and nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice after GZ-161 treatment correlated with amelioration of neurodegeneration, as indicated by serum Nf-L levels. Notably, consistent with the age-related progression of neuroaxonal damage, there was a clear age-related increase in serum Nf-L levels with the most significant increase in aged <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> mice (<xref ref-type="fig" rid="fig8">Figure 8B</xref>). Serum levels of Nf-L and GlcSph were strongly correlated (<italic>r</italic> = 0.8344, p&lt;0.0001), consistent with a direct link between lysosomal generation of toxic GlcSph and neuroaxonal injury (<xref ref-type="fig" rid="fig8">Figure 8C</xref>). Together, these data support the notion that GlcSph (and GluCer) reduction therapy with the brain-penetrant GCS inhibitor GZ-161 ameliorates neurodegeneration in nGD mice. Moreover, the results suggest that serum Nf-L and GlcSph are promising biomarkers of neurodegeneration in <italic>Gba</italic> deficiency.</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Clinical evaluation of ApoE and neurofilament light chain (Nf-L) as biomarkers of Gaucher disease (GD)-associated neurodegeneration.</title><p>(<bold>A</bold>) Quantitative analysis of serum Nf-L levels in neuronopathic Gaucher disease (nGD), nGD <italic>Cx3cr1</italic><sup>Cre/+</sup>, and nGD <italic>Nes</italic><sup>Cre/+</sup> mice with and without GZ-161 treatment compared with the vehicle-treated controls (n = 4–10 mice/group; two independent experiments). (<bold>B</bold>) Comparison of serum Nf-L levels between young and aged <italic>Gba</italic><sup>fl/fl</sup><italic>Cx3cr1</italic><sup>Cre/wt</sup> mice along with control mice (n = 8–11 mice/group). (<bold>C</bold>) Correlation between serum GlcSph and Nf-L levels in nGD, nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice, nGD <italic>Nes</italic><sup>Cre/+</sup>, and control mice. The p-value obtained from Spearman’s rank correlation coefficient test was &lt;0.0001 (n = 69 mice). (<bold>D</bold>) Quantitative analysis of serum Nf-L levels (log2 scale) in GD3 patients (n = 5) compared with age-matched GD1 patient (n = 6). (<bold>E</bold>) Quantitative analysis of serum levels glucosylsphingosine (GlcSph) in GD3 patients (n = 3) compared with age-matched GD1 patient (n = 6). (<bold>F</bold>) Quantitative analysis of serum Nf-L levels (log2 scale) in young GD1 patients (n = 12) compared with adult GD1 patient (n = 25) and adult healthy controls (n = 28). (<bold>G</bold>) Signal intensities of lysophosphatidylcholine (LysoPC) identified by MALDI across <italic>Gba</italic><sup>fl/fl</sup><italic>Cx3cr1</italic><sup>Cre/wt</sup> mice treated with either vehicle or GZ161 and control mice brain. The color bars in MALDI images show signal intensity: blue to red indicates low to high levels. (<bold>H</bold>) Quantitative analysis of serum levels of LysoPC 16:1 species in young GD1 patients (n = 12) compared with adult GD1 patient (n = 26). (<bold>I</bold>) Graph represents ApE levels in the sera of untreated GD1 patients (n = 55) and healthy controls (n = 43). (<bold>J</bold>) Graph represents ApoE levels in the sera of untreated GD1 patients (n = 55) and after enzyme replacement therapy (ERT) (n = 55). (<bold>K</bold>) Correlation between serum GlcSph and ApoE levels in sera of GD1 patients. The p-value obtained from Pearson’s correlation test was &lt;0.001 (n = 21 patients). (<bold>L</bold>) Receiver-operating characteristic (ROC) curves for serum ApoE expression in GD1 patients and area under the curve (AUC). Means ± SEM are shown. Differences between groups were analyzed using unpaired <italic>t</italic>-test. (<bold>A, B</bold>) Mann–Whitey test (<bold>C, E, H, I</bold>), two-tailed. *p&lt;0.05, **p&lt;0.001, and ***p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Expression of ApoE and <italic>Abca1</italic> in different brain cell types of neuronopathic Gaucher disease (nGD) mice.</title><p>(<bold>A</bold>) Histogram showing differential expression of ApoE in microglia, astrocyte, neuron, and oligodendrocyte cluster from nGD (2 weeks old), nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> (2 and 6 weeks old, respectively), and corresponding control mice. (<bold>B</bold>) Histogram showing expression of <italic>Abca1</italic> in oligodendrocyte, microglia, astrocyte, and neuron from nGD (2 weeks old), nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> (2 and 6 weeks old, respectively), nGD <italic>Nes</italic><sup>Cre/+</sup>, and corresponding control mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig8-figsupp1-v2.tif"/></fig></fig-group><p>Our findings of serum Nf-L correlating with severity of neurodegeneration as well as serum levels of GlcSph in various permutations of nGD mice model for the first time reveal that such circulating biomarkers may exist not only for tracking the severity of neurodegeneration but also for monitoring the response to therapy. Therefore, we conducted an analysis of several candidate biomarkers of neurodegeneration in patients with GD (<xref ref-type="fig" rid="fig9">Figure 9</xref>). We compared serum Nf-L levels in GD3 patients with early mild neurodegenerative symptoms with age-matched GD1 patients who did not develop early-onset neurodegeneration. Serum Nf-L levels were elevated in GD3 patients compared to those in GD1 (<xref ref-type="fig" rid="fig8">Figure 8D</xref>). This increase in serum Nf-L levels was associated with elevated serum GlcSph levels in GD3 patients (<xref ref-type="fig" rid="fig8">Figure 8E</xref>). Akin to age-related increases in serum Nf-L levels in <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> mice, indicative of age-related progression of neuroaxonal damage (<xref ref-type="fig" rid="fig8">Figure 8B</xref>), serum Nf-L levels were significantly elevated in adult GD1 patients compared to children with GD1 and adult healthy controls (<xref ref-type="fig" rid="fig8">Figure 8F</xref>). This is significant as adult GD1 patients are at an increased risk of PD/LBD. Interestingly, LysoPC was present with an exceptionally strong signal in the microglia in the cerebral cortex and midbrain regions of untreated <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> mice. Intensity of LysoPC accumulation in brain microglia was significantly reduced by GZ-161 treatment (<xref ref-type="fig" rid="fig8">Figure 8G</xref>). The finding of striking LysoPC accumulation in <italic>Gba</italic>-deficient microglia prompted us to measure LysoPC in the sera of GD1 patients, comparing young and older patients. Similar to the results with serum Nf-L, older GD1 patients exhibited increased serum levels of LysoPC 16:1 (<xref ref-type="fig" rid="fig8">Figure 8H</xref>). These findings raise the possibility of broader involvement of lipid metabolism pathways beyond the primary <italic>Gba</italic> defect in GD and fuller understanding could lead to useful biomarkers for the clinic and role of co-regulated lipids in pathophysiology that may be targeted by treatments for GD.</p><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Remark flowchart.</title><p>Flow diagram of the study cohort used in the study.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79830-fig9-v2.tif"/></fig><p>Next, building upon the striking induction of ApoE expression beyond the astrocytes seen in our study, we examined ApoE as a potential biomarker for GD. In steady state, ApoE plays a critical role in lipid metabolism in the brain, with the largest contribution from astrocytes. In disease settings, the induction of ApoE is among the key signature genes of DAM. Thus, the role of ApoE in the brain is multifaceted, including lipid homeostasis, modulation of neuroinflammation, and neuronal repair (<xref ref-type="bibr" rid="bib50">Serrano-Pozo et al., 2021</xref>). Hence, in the context of an inborn error of lipid metabolism exemplified by GD with prominent neurodegeneration, it is highly relevant to explore ApoE expression in various brain cells in different states of nGD. We found prominent ApoE expression in astrocytes and activated microglia in nGD mice. Additionally, there was a striking induction of ApoE in multiple neuronal cell types as well as in endothelial cells (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A</xref>). Interestingly, there was concomitant induction of <italic>Abca1</italic>, suggesting coupling with increased efflux of accumulating pathogenic lipids from cells in <italic>Gba</italic> deficient brain (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1B</xref>). Therefore, we measured ApoE in the sera of 55 adults with confirmed GD1 before and after ERT, which dramatically lowered GlcSph and reversed systemic clinical manifestations. Sera of untreated GD1 patients showed markedly increased levels of ApoE compared to healthy control sera (<xref ref-type="fig" rid="fig8">Figure 8I</xref>). ERT resulted in a marked decrease in ApoE levels (<xref ref-type="fig" rid="fig8">Figure 8J</xref>). Notably, elevated ApoE levels correlated significantly with serum GlcSph levels (<xref ref-type="fig" rid="fig8">Figure 8K</xref>). The sensitivity and specificity of ApoE as a biomarker were underscored by the area under the receiver operator characteristic (ROC) of 0.92 (p&lt;0.001) (<xref ref-type="fig" rid="fig8">Figure 8L</xref>), similar to that seen in other accepted biomarkers of GD, such as chitotriosidase, gpNMB, and GlcSph (<xref ref-type="bibr" rid="bib2">Aerts et al., 2011</xref>; <xref ref-type="bibr" rid="bib41">Murugesan et al., 2016</xref>).</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>There is limited information of how <italic>Gba</italic> deficiency affects the cross-talk between immune cells and neuronal cell types due to accumulating glucosylceramide lipids. Hence, there are no effective therapies for devastating neurodegenerative diseases associated with <italic>Gba</italic> mutations, and clinical trials have been severely hindered by a lack of reliable biomarkers. Previous studies in mice have suggested utility of brain permeant GCS inhibitor as treatment for neuronopathic GD but a clinical trial of miglustat (N-butyldeoxynojirimycin), an iminosugar, did not improve neurological end points in GD3 (<xref ref-type="bibr" rid="bib48">Schiffmann et al., 2008</xref>). Subsequently, more potent GCS inhibitors based on ceramide analogs have shown more promise in genetic nGD model and in chemically induced model (<xref ref-type="bibr" rid="bib8">Blumenreich et al., 2021</xref>; <xref ref-type="bibr" rid="bib11">Cabrera-Salazar et al., 2012</xref>; <xref ref-type="bibr" rid="bib51">Shayman, 2010</xref>; <xref ref-type="bibr" rid="bib64">Wilson et al., 2020</xref>).</p><p>To delineate the impact of glycosphingolipid accumulation, identify candidate biomarkers, and assess the impact of GluCer/GlcSph lowering using a potent inhibitor of GCS, we developed an array of genetic mouse models to probe the cell-specific roles of <italic>Gba</italic> at single-cell resolution. Our models recapitulated both early- as well as late-onset neurodegenerative GD that provided unique insights through resolving the heterogeneity of brain macrophage populations. Our findings implicate the essential role of GlcCer-laden microglia and immune infiltrates (including CCR2<sup>+</sup> MFs defined as CD11b<sup>hi</sup> CD45<sup>+</sup>CCR2<sup>+</sup> CD64<sup>+</sup> TIMD4<sup>-</sup> population and NK cells) and astrocytes in orchestrating neuroinflammation. Our studies identified key attributes of GD associated neuroinflammation in the form of attrition of homeostatic microglia, emergence of DAM, influx of CCR2<sup>+</sup> MFs, activation of the ISG pathway, and infiltration of activated NK cells. Massive cellular accumulation of GluCer/GlcSph due to <italic>Gba</italic> deficiency in microglia, immune infiltrates, and neurons resulted in early onset of neuroinflammation, which was attenuated into late-onset neurodegenerative disease by selective rescue of <italic>Gba</italic> in either microglia or neurons as well as by pharmacological reduction of GluCer/GlcSph in the brain using GCS inhibitor. Interestingly, inflammatory microglia also expressed several proposed biomarkers of GD, which we and others have reported such as complement pathway genes, gpNMB, cathepsin D, and cathepsin S (<xref ref-type="bibr" rid="bib3">Afinogenova et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Kramer et al., 2016</xref>; <xref ref-type="bibr" rid="bib38">Mistry et al., 2014</xref>; <xref ref-type="bibr" rid="bib41">Murugesan et al., 2016</xref>; <xref ref-type="bibr" rid="bib45">Pandey et al., 2017</xref>; <xref ref-type="bibr" rid="bib59">Vitner et al., 2010</xref>; <xref ref-type="bibr" rid="bib67">Zigdon et al., 2015</xref>). Rescue of <italic>Gba</italic> in neuronal progenitors increased survival, but nevertheless, markedly shortened compared to control mice, requiring humane end point sacrifice due to morbid conditions and autistic behavior, reminiscent of human GD3 (<xref ref-type="bibr" rid="bib1">Abdelwahab et al., 2017</xref>; <xref ref-type="bibr" rid="bib7">Bilbo and Stevens, 2017</xref>; <xref ref-type="bibr" rid="bib65">Wong et al., 2004</xref>). Late-onset neurodegenerative disease observed in some patients with GD1 (<xref ref-type="bibr" rid="bib10">Bultron et al., 2010</xref>) appeared to be recapitulated in <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> mice having slow progressive neuroinflammation with accumulation of GluCer lipids in the brain, elevated serum Nf-L, and DAM gene signatures.</p><p>In our nGD mouse models with robust neuroinflammation, we found prominent GzmA<sup>+</sup> NK cell infiltration. Restoring <italic>Gba</italic> function in microglia alone showed limited effect on NK cell infiltration; however, treatment with GCS inhibitor not only offset GluCer/GlcSph buildup, but also exhibited a novel immunomodulatory effect by abrogating NK cell activation. Therefore, combination therapy with GCS inhibitors and microglia-targeted therapeutics (<xref ref-type="bibr" rid="bib52">Shibuya et al., 2022</xref>) merits further exploration. In general, the immune response of NK cells is fine-tuned by a balance of stimulatory and inhibitory signals based on a distinct receptor repertoire. In certain pathological states, injured neurons display activating NKG2D ligands that target them for NK cell-mediated injury (<xref ref-type="bibr" rid="bib18">Davies et al., 2019</xref>). A potential mechanism relevant to our findings in nGD for NK cell involvement in neurodegeneration is via HLA-1 recognition by NK cells through its inhibitory receptors Ly49 (in mice) and KIR (in humans), which mediate self/non-self-discrimination (<xref ref-type="bibr" rid="bib15">Colonna and Samaridis, 1995</xref>; <xref ref-type="bibr" rid="bib30">Karlhofer et al., 1992</xref>). Thus, downregulation of HLA-1 surface expression is envisioned to trigger NK cell-mediated neuronal injury due to ‘missing self.’ Consistent with this notion, a recent study reported that altered cell surface GSL repertoire limited accessibility of HLA-1 by immune cells, such as CD8 T cells and NK cells, and treatment with a GCS inhibitor (N-butyl-deoxynojirimycin) fully restored accessibility to HLA-1 (<xref ref-type="bibr" rid="bib28">Jongsma et al., 2021</xref>). Indeed, in our nGD models, a more potent GCS inhibitor, GZ-161, was highly effective in reversing NK cell activation concomitant with marked reduction of brain glucosylceramide lipids. Therefore, it seems likely that in severe <italic>Gba</italic> deficiency, causing early-onset neurodegeneration, altered cell surface GSLs in neurons impair the accessibility of HLA-1 by NK cell receptors, triggering activation and neuronal degeneration.</p><p>Our studies show remarkable efficacy of potent brain penetrant GCS inhibitor, GZ-161, in reducing GluCer and GlcSph in immune and neuronal cells of nGD mice concomitant with amelioration of neuroinflammation and neurodegeneration. A prior clinical trial of GCS inhibitor N-butyldeoxynojirimycin in GD3 showed no effect on neurological symptoms (<xref ref-type="bibr" rid="bib48">Schiffmann et al., 2008</xref>). In such clinical trials, patients have established advanced neurological disease that can hinder assessment of full therapeutic effects. Therefore, a major unmet need in neurodegenerative disease associated with <italic>GBA</italic> mutations is the lack of suitable biomarkers to detect neurodegeneration before onset of overt neurological symptoms, such as saccades, ataxia, or seizures. We aimed to leverage the findings from our nGD models to generate novel biomarkers. In our study, neuroaxonal injury was reflected in the elevation of serum Nf-L (<xref ref-type="bibr" rid="bib23">Gaetani et al., 2019</xref>; <xref ref-type="bibr" rid="bib63">Weinhofer et al., 2021</xref>). Data from our nGD models with different rates of neurodegeneration revealed Nf-L as a strong serum biomarker of neurodegeneration that correlated with survival as well as with serum GlcSph. The candidacy of these biomarkers is especially bolstered by the finding of rising levels of serum Nf-L and GlcSph in <italic>Gba<sup>fl/fl</sup>Cx3cr1</italic><sup>Cre/+</sup> mice as the source of these biomarkers in these mice is from within the brain. These findings are promising to explore serum Nf-L as a biomarker of neurodegeneration to help address significant challenges in the management of patients with GD, that is, distinguish between GD2 and early-onset GD3, track subclinical neurodegeneration in the extremely variable GD3, to help individualize future therapies and identify GD1 individuals at risk for PD/LBD. Indeed, we found that serum Nf-L levels were higher in GD3 patients than in age-matched GD1 patients. Moreover, Nf-L levels were higher in older patients with GD1 compared to younger patients. This is significant considering that adult GD1 patients are at a risk of developing PD/LBD. In this context, our findings of serum Nf-L as a strong biomarker raise the exciting prospect of detecting subclinical neurodegeneration, allowing early initiation of treatment to achieve better clinical outcome. There is an emerging consensus that providing treatment before the onset of overt disease manifestations offers prospects for best outcomes in inborn errors of metabolism. Studying larger cohorts of patients stratified by different types of neurodegenerations due to <italic>GBA</italic> mutations may aid further biomarker validation. The second promising biomarker emanates from striking induction of ApoE in all neuronal cell types beyond astrocytes and DAM in nGD models. Our translational result of striking elevation of ApoE levels in GD patients that correlates with GlcSph levels is compelling to explore the role of ApoE in neurodegeneration associated with <italic>GBA</italic> mutations. Indeed, a recent study showed increased prevalence of Apo E4 allele in heterozygote carriers of GBA mutations who develop PD (<xref ref-type="bibr" rid="bib53">Shiner et al., 2021</xref>).</p><p>Overall, through our systematic single-cell transcriptome analysis, we identified cell populations, immunological and pathophysiological mechanisms underlying neurodegeneration associated with <italic>GBA</italic> deficiency. This approach also yielded therapeutic targets and promising biomarkers for clinical validation to improve patient care and aid clinical trials.</p><sec id="s4-1"><title>Limitations of the study</title><p>There are several limitations to our studies. In <italic>Gba</italic><sup>lsl/lsl</sup> model of fulminant neurodegeneration that phenocopies human GD2, GCS inhibitor prolonged survival significantly but the overall effect was modest. This is likely related to challenges in administering GCS inhibitor by gavage in the first days of life. While our study showed a critical role for both neuronal and microglial <italic>Gba</italic> in Gaucher-related neurodegeneration and involvement of NK cells, it was beyond the scope of the current work to delineate a hierarchy of neuronal populations according to their vulnerability to toxic accumulation of lipids in setting of <italic>Gba</italic> deficiency and compensatory or pathological interactions with glial cells, infiltrating NK cells, and other immune cells. With regard to application of our findings to human health, an earlier randomized trial of GCS inhibitor, N-butyldeoxynojirimycin was not successful in ameliorating neurological symptoms. However, it is a relatively weak inhibitor of GCS with more potent inhibitory off-target effects (<xref ref-type="bibr" rid="bib48">Schiffmann et al., 2008</xref>). However, more specific and potent GCS inhibitors are showing early promise (<xref ref-type="bibr" rid="bib49">Schiffmann et al., 2020</xref>; <xref ref-type="bibr" rid="bib64">Wilson et al., 2020</xref>).</p></sec><sec id="s4-2"><title>Materials availability</title><p>All materials in this study are available upon request.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>&quot;JG is an employee of Sanofi and received stock and options as part of compensation. JG received tissues samples from Yale for data generation. The author has no other competing interests to declare&quot;</p></fn><fn fn-type="COI-statement" id="conf4"><p>&quot;ET is an employee of Sanofi. The author has no other competing interests to declare&quot;</p></fn><fn fn-type="COI-statement" id="conf5"><p>T-H N was previously an employee of Sanofi. The author has no other competing interests to declare&quot;</p></fn><fn fn-type="COI-statement" id="conf6"><p>LG is an employee of Sanofi and holds stocks in Sanofi. The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf7"><p>MK was previously an employee of Sanofi and holds stocks in Sanofi. The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf8"><p>HW was previously an employee of Sanofi. The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf9"><p>HW (now retired) was previously an employee of Sanofi and holds stocks in Sanofi. The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf10"><p>BZ is an employee of Sanofi. The author has no other competing interests to declare</p></fn><fn fn-type="COI-statement" id="conf11"><p>KK is an employee of Sanofi. The author has no other competing interests to declare</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con4"><p>Resources, Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con5"><p>Resources, Data curation, Software, Formal analysis</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con7"><p>Formal analysis</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con11"><p>Formal analysis</p></fn><fn fn-type="con" id="con12"><p>Supervision</p></fn><fn fn-type="con" id="con13"><p>Resources, Software, Formal analysis</p></fn><fn fn-type="con" id="con14"><p>Methodology</p></fn><fn fn-type="con" id="con15"><p>Supervision</p></fn><fn fn-type="con" id="con16"><p>Supervision</p></fn><fn fn-type="con" id="con17"><p>Conceptualization, Funding acquisition, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Informed consent, and consent to publish, was obtained from the patients and the study was approved by the Human Investigations Committee of Yale School of Medicine.</p></fn><fn fn-type="other"><p>Mice were housed in the animal facility of Yale university in New Haven. All animal experiments were conducted in compliance with institutional regulations under authorized protocol (2016-10872) approved by the Institutional Animal Care and Use Committee.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-79830-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for Figure 2 - figure supplement 1 and Figure 3 - figure supplement 1. Raw data files for Single cell and single nucleus RNA sequencing are deposited with NCBI GEO under accession numbers GSE207765, GSE207766 and GSE207768.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Boddupalli</surname><given-names>CS</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>scRNA seq analysis on immune cells isolated from nGD mice brain</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE207766">GSE207766</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Boddupalli</surname><given-names>CS</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Belinsky</surname><given-names>G</given-names></name><name><surname>Gans</surname><given-names>J</given-names></name><name><surname>Teeple</surname><given-names>E</given-names></name><name><surname>Nguyen</surname><given-names>T-H</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Kramer</surname><given-names>ML</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Davison</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Bailin</surname><given-names>DJZ</given-names></name><name><surname>Klinger</surname><given-names>K</given-names></name><name><surname>Mistry</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>RNA and scRNA seq analyses on immune cells isolated from nGD mice brain</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE207768">GSE207768</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Boddupalli</surname><given-names>CS</given-names></name><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Belinsky</surname><given-names>G</given-names></name><name><surname>Gans</surname><given-names>J</given-names></name><name><surname>Teeple</surname><given-names>E</given-names></name><name><surname>Nguyen</surname><given-names>T-HN</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Kramer</surname><given-names>ML</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Davison</surname><given-names>M</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Vidyadhara</surname><given-names>DJ</given-names></name><name><surname>Bailin</surname><given-names>DJZ</given-names></name><name><surname>Klinger</surname><given-names>K</given-names></name><name><surname>Mistry</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>RNA seq analysis on immune cells isolated from nGD mice brain</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE207765">GSE207765</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Dr Stefan Karlsson for generously sharing lsl/lsl, nGD mice. We also thank Dr. Sreeganga Chandra for suggestions on mice behavioral tests. This study was funded by a research grant from Sanofi (to PKM).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelwahab</surname><given-names>M</given-names></name><name><surname>Potegal</surname><given-names>M</given-names></name><name><surname>Shapiro</surname><given-names>EG</given-names></name><name><surname>Nestrasil</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Previously unrecognized behavioral phenotype in Gaucher disease type 3</article-title><source>Neurology. Genetics</source><volume>3</volume><elocation-id>e158</elocation-id><pub-id pub-id-type="doi">10.1212/NXG.0000000000000158</pub-id><pub-id pub-id-type="pmid">28634598</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aerts</surname><given-names>J</given-names></name><name><surname>Kallemeijn</surname><given-names>WW</given-names></name><name><surname>Wegdam</surname><given-names>W</given-names></name><name><surname>Joao Ferraz</surname><given-names>M</given-names></name><name><surname>van Breemen</surname><given-names>MJ</given-names></name><name><surname>Dekker</surname><given-names>N</given-names></name><name><surname>Kramer</surname><given-names>G</given-names></name><name><surname>Poorthuis</surname><given-names>BJ</given-names></name><name><surname>Groener</surname><given-names>JEM</given-names></name><name><surname>Cox-Brinkman</surname><given-names>J</given-names></name><name><surname>Rombach</surname><given-names>SM</given-names></name><name><surname>Hollak</surname><given-names>CEM</given-names></name><name><surname>Linthorst</surname><given-names>GE</given-names></name><name><surname>Witte</surname><given-names>MD</given-names></name><name><surname>Gold</surname><given-names>H</given-names></name><name><surname>van der Marel</surname><given-names>GA</given-names></name><name><surname>Overkleeft</surname><given-names>HS</given-names></name><name><surname>Boot</surname><given-names>RG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies</article-title><source>Journal of Inherited Metabolic Disease</source><volume>34</volume><fpage>605</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1007/s10545-011-9308-6</pub-id><pub-id pub-id-type="pmid">21445610</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afinogenova</surname><given-names>Y</given-names></name><name><surname>Ruan</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Kleytman</surname><given-names>N</given-names></name><name><surname>Pastores</surname><given-names>G</given-names></name><name><surname>Lischuk</surname><given-names>A</given-names></name><name><surname>Mistry</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Aberrant progranulin, YKL-40, cathepsin D and cathepsin S in Gaucher disease</article-title><source>Molecular Genetics and Metabolism</source><volume>128</volume><fpage>62</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2019.07.014</pub-id><pub-id pub-id-type="pmid">31358474</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aharon-Peretz</surname><given-names>J</given-names></name><name><surname>Rosenbaum</surname><given-names>H</given-names></name><name><surname>Gershoni-Baruch</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Mutations in the glucocerebrosidase gene and Parkinson’s disease in Ashkenazi Jews</article-title><source>The New England Journal of Medicine</source><volume>351</volume><fpage>1972</fpage><lpage>1977</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa033277</pub-id><pub-id pub-id-type="pmid">15525722</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batiuk</surname><given-names>MY</given-names></name><name><surname>Martirosyan</surname><given-names>A</given-names></name><name><surname>Wahis</surname><given-names>J</given-names></name><name><surname>de Vin</surname><given-names>F</given-names></name><name><surname>Marneffe</surname><given-names>C</given-names></name><name><surname>Kusserow</surname><given-names>C</given-names></name><name><surname>Koeppen</surname><given-names>J</given-names></name><name><surname>Viana</surname><given-names>JF</given-names></name><name><surname>Oliveira</surname><given-names>JF</given-names></name><name><surname>Voet</surname><given-names>T</given-names></name><name><surname>Ponting</surname><given-names>CP</given-names></name><name><surname>Belgard</surname><given-names>TG</given-names></name><name><surname>Holt</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Identification of region-specific astrocyte subtypes at single cell resolution</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>1220</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-14198-8</pub-id><pub-id pub-id-type="pmid">32139688</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belarbi</surname><given-names>K</given-names></name><name><surname>Cuvelier</surname><given-names>E</given-names></name><name><surname>Bonte</surname><given-names>MA</given-names></name><name><surname>Desplanque</surname><given-names>M</given-names></name><name><surname>Gressier</surname><given-names>B</given-names></name><name><surname>Devos</surname><given-names>D</given-names></name><name><surname>Chartier-Harlin</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Glycosphingolipids and neuroinflammation in Parkinson’s disease</article-title><source>Molecular Neurodegeneration</source><volume>15</volume><elocation-id>59</elocation-id><pub-id pub-id-type="doi">10.1186/s13024-020-00408-1</pub-id><pub-id pub-id-type="pmid">33069254</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilbo</surname><given-names>S</given-names></name><name><surname>Stevens</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Microglia: The brain’s first responders</article-title><source>Cerebrum: The Dana Forum on Brain Science</source><volume>1</volume><elocation-id>cer-14-17</elocation-id><pub-id pub-id-type="pmid">30210663</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blumenreich</surname><given-names>S</given-names></name><name><surname>Yaacobi</surname><given-names>C</given-names></name><name><surname>Vardi</surname><given-names>A</given-names></name><name><surname>Barav</surname><given-names>OB</given-names></name><name><surname>Vitner</surname><given-names>EB</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Cheng</surname><given-names>SH</given-names></name><name><surname>Sardi</surname><given-names>SP</given-names></name><name><surname>Futerman</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Substrate reduction therapy using Genz-667161 reduces levels of pathogenic components in a mouse model of neuronopathic forms of Gaucher disease</article-title><source>Journal of Neurochemistry</source><volume>156</volume><fpage>692</fpage><lpage>701</lpage><pub-id pub-id-type="doi">10.1111/jnc.15136</pub-id><pub-id pub-id-type="pmid">32743826</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bodennec</surname><given-names>J</given-names></name><name><surname>Pelled</surname><given-names>D</given-names></name><name><surname>Riebeling</surname><given-names>C</given-names></name><name><surname>Trajkovic</surname><given-names>S</given-names></name><name><surname>Futerman</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide</article-title><source>FASEB Journal</source><volume>16</volume><fpage>1814</fpage><lpage>1816</lpage><pub-id pub-id-type="doi">10.1096/fj.02-0149fje</pub-id><pub-id pub-id-type="pmid">12223447</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bultron</surname><given-names>G</given-names></name><name><surname>Kacena</surname><given-names>K</given-names></name><name><surname>Pearson</surname><given-names>D</given-names></name><name><surname>Boxer</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Sathe</surname><given-names>S</given-names></name><name><surname>Pastores</surname><given-names>G</given-names></name><name><surname>Mistry</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The risk of Parkinson’s disease in type 1 Gaucher disease</article-title><source>Journal of Inherited Metabolic Disease</source><volume>33</volume><fpage>167</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.1007/s10545-010-9055-0</pub-id><pub-id pub-id-type="pmid">20177787</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabrera-Salazar</surname><given-names>MA</given-names></name><name><surname>Deriso</surname><given-names>M</given-names></name><name><surname>Bercury</surname><given-names>SD</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Lydon</surname><given-names>JT</given-names></name><name><surname>Weber</surname><given-names>W</given-names></name><name><surname>Pande</surname><given-names>N</given-names></name><name><surname>Cromwell</surname><given-names>MA</given-names></name><name><surname>Copeland</surname><given-names>D</given-names></name><name><surname>Leonard</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>SH</given-names></name><name><surname>Scheule</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Systemic delivery of a glucosylceramide synthase inhibitor reduces CNS substrates and increases lifespan in a mouse model of type 2 Gaucher disease</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e43310</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0043310</pub-id><pub-id pub-id-type="pmid">22912851</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021a</year><article-title>Microglia in Alzheimer’s disease at single-cell level: Are there common patterns in humans and mice?</article-title><source>The Journal of Experimental Medicine</source><volume>218</volume><elocation-id>e20202717</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20202717</pub-id><pub-id pub-id-type="pmid">34292312</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>He</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2021">2021b</year><article-title>The value of long noncoding RNAs for predicting the recurrence of endometriosis: A protocol for meta-analysis and bioinformatics analysis</article-title><source>Medicine</source><volume>100</volume><elocation-id>e26036</elocation-id><pub-id pub-id-type="doi">10.1097/MD.0000000000026036</pub-id><pub-id pub-id-type="pmid">34032726</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>SM</given-names></name><name><surname>Vardi</surname><given-names>A</given-names></name><name><surname>Platt</surname><given-names>N</given-names></name><name><surname>Futerman</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Absence of infiltrating peripheral myeloid cells in the brains of mouse models of lysosomal storage disorders</article-title><source>Journal of Neurochemistry</source><volume>148</volume><fpage>625</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1111/jnc.14483</pub-id><pub-id pub-id-type="pmid">29900534</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Samaridis</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells</article-title><source>Science</source><volume>268</volume><fpage>405</fpage><lpage>408</lpage><pub-id pub-id-type="doi">10.1126/science.7716543</pub-id><pub-id pub-id-type="pmid">7716543</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname><given-names>T</given-names></name><name><surname>Lachmann</surname><given-names>R</given-names></name><name><surname>Hollak</surname><given-names>C</given-names></name><name><surname>Aerts</surname><given-names>J</given-names></name><name><surname>van Weely</surname><given-names>S</given-names></name><name><surname>Hrebícek</surname><given-names>M</given-names></name><name><surname>Platt</surname><given-names>F</given-names></name><name><surname>Butters</surname><given-names>T</given-names></name><name><surname>Dwek</surname><given-names>R</given-names></name><name><surname>Moyses</surname><given-names>C</given-names></name><name><surname>Gow</surname><given-names>I</given-names></name><name><surname>Elstein</surname><given-names>D</given-names></name><name><surname>Zimran</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Novel oral treatment of Gaucher’s disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis</article-title><source>Lancet</source><volume>355</volume><fpage>1481</fpage><lpage>1485</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02161-9</pub-id><pub-id pub-id-type="pmid">10801168</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crusio</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Genetic dissection of mouse exploratory behaviour</article-title><source>Behavioural Brain Research</source><volume>125</volume><fpage>127</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1016/s0166-4328(01)00280-7</pub-id><pub-id pub-id-type="pmid">11682103</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>AJ</given-names></name><name><surname>Kim</surname><given-names>HW</given-names></name><name><surname>Gonzalez-Cano</surname><given-names>R</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Back</surname><given-names>SK</given-names></name><name><surname>Roh</surname><given-names>SE</given-names></name><name><surname>Johnson</surname><given-names>E</given-names></name><name><surname>Gabriac</surname><given-names>M</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Bae</surname><given-names>YC</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>KM</given-names></name><name><surname>Na</surname><given-names>HS</given-names></name><name><surname>Riva</surname><given-names>P</given-names></name><name><surname>Latremoliere</surname><given-names>A</given-names></name><name><surname>Rinaldi</surname><given-names>S</given-names></name><name><surname>Ugolini</surname><given-names>S</given-names></name><name><surname>Costigan</surname><given-names>M</given-names></name><name><surname>Oh</surname><given-names>SB</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Natural killer cells degenerate intact sensory afferents following nerve injury</article-title><source>Cell</source><volume>176</volume><fpage>716</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.12.022</pub-id><pub-id pub-id-type="pmid">30712871</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dick</surname><given-names>SA</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Hamidzada</surname><given-names>H</given-names></name><name><surname>Nejat</surname><given-names>S</given-names></name><name><surname>Nechanitzky</surname><given-names>R</given-names></name><name><surname>Vohra</surname><given-names>S</given-names></name><name><surname>Mueller</surname><given-names>B</given-names></name><name><surname>Zaman</surname><given-names>R</given-names></name><name><surname>Kantores</surname><given-names>C</given-names></name><name><surname>Aronoff</surname><given-names>L</given-names></name><name><surname>Momen</surname><given-names>A</given-names></name><name><surname>Nechanitzky</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>WY</given-names></name><name><surname>Ramachandran</surname><given-names>P</given-names></name><name><surname>Crome</surname><given-names>SQ</given-names></name><name><surname>Becher</surname><given-names>B</given-names></name><name><surname>Cybulsky</surname><given-names>MI</given-names></name><name><surname>Billia</surname><given-names>F</given-names></name><name><surname>Keshavjee</surname><given-names>S</given-names></name><name><surname>Mital</surname><given-names>S</given-names></name><name><surname>Robbins</surname><given-names>CS</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name><name><surname>Epelman</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Three tissue resident macrophage subsets coexist across organs with conserved origins and life cycles</article-title><source>Science Immunology</source><volume>7</volume><elocation-id>eabf7777</elocation-id><pub-id pub-id-type="doi">10.1126/sciimmunol.abf7777</pub-id><pub-id pub-id-type="pmid">34995099</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Enquist</surname><given-names>IB</given-names></name><name><surname>Lo Bianco</surname><given-names>C</given-names></name><name><surname>Ooka</surname><given-names>A</given-names></name><name><surname>Nilsson</surname><given-names>E</given-names></name><name><surname>Månsson</surname><given-names>JE</given-names></name><name><surname>Ehinger</surname><given-names>M</given-names></name><name><surname>Richter</surname><given-names>J</given-names></name><name><surname>Brady</surname><given-names>RO</given-names></name><name><surname>Kirik</surname><given-names>D</given-names></name><name><surname>Karlsson</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Murine models of acute neuronopathic Gaucher disease</article-title><source>PNAS</source><volume>104</volume><fpage>17483</fpage><lpage>17488</lpage><pub-id pub-id-type="doi">10.1073/pnas.0708086104</pub-id><pub-id pub-id-type="pmid">17954912</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farfel-Becker</surname><given-names>T</given-names></name><name><surname>Vitner</surname><given-names>EB</given-names></name><name><surname>Futerman</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Animal models for Gaucher disease research</article-title><source>Disease Models &amp; Mechanisms</source><volume>4</volume><fpage>746</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1242/dmm.008185</pub-id><pub-id pub-id-type="pmid">21954067</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Finak</surname><given-names>G</given-names></name><name><surname>McDavid</surname><given-names>A</given-names></name><name><surname>Yajima</surname><given-names>M</given-names></name><name><surname>Deng</surname><given-names>J</given-names></name><name><surname>Gersuk</surname><given-names>V</given-names></name><name><surname>Shalek</surname><given-names>AK</given-names></name><name><surname>Slichter</surname><given-names>CK</given-names></name><name><surname>Miller</surname><given-names>HW</given-names></name><name><surname>McElrath</surname><given-names>MJ</given-names></name><name><surname>Prlic</surname><given-names>M</given-names></name><name><surname>Linsley</surname><given-names>PS</given-names></name><name><surname>Gottardo</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data</article-title><source>Genome Biology</source><volume>16</volume><elocation-id>278</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-015-0844-5</pub-id><pub-id pub-id-type="pmid">26653891</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaetani</surname><given-names>L</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Calabresi</surname><given-names>P</given-names></name><name><surname>Di Filippo</surname><given-names>M</given-names></name><name><surname>Parnetti</surname><given-names>L</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Neurofilament light chain as a biomarker in neurological disorders</article-title><source>Journal of Neurology, Neurosurgery, and Psychiatry</source><volume>90</volume><fpage>870</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1136/jnnp-2018-320106</pub-id><pub-id pub-id-type="pmid">30967444</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gegg</surname><given-names>ME</given-names></name><name><surname>Menozzi</surname><given-names>E</given-names></name><name><surname>Schapira</surname><given-names>AHV</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Glucocerebrosidase-associated Parkinson disease: Pathogenic mechanisms and potential drug treatments</article-title><source>Neurobiology of Disease</source><volume>166</volume><elocation-id>105663</elocation-id><pub-id pub-id-type="doi">10.1016/j.nbd.2022.105663</pub-id><pub-id pub-id-type="pmid">35183702</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grabowski</surname><given-names>GA</given-names></name><name><surname>Antommaria</surname><given-names>AHM</given-names></name><name><surname>Kolodny</surname><given-names>EH</given-names></name><name><surname>Mistry</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Gaucher disease: Basic and translational science needs for more complete therapy and management</article-title><source>Molecular Genetics and Metabolism</source><volume>132</volume><fpage>59</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2020.12.291</pub-id><pub-id pub-id-type="pmid">33419694</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habib</surname><given-names>N</given-names></name><name><surname>McCabe</surname><given-names>C</given-names></name><name><surname>Medina</surname><given-names>S</given-names></name><name><surname>Varshavsky</surname><given-names>M</given-names></name><name><surname>Kitsberg</surname><given-names>D</given-names></name><name><surname>Dvir-Szternfeld</surname><given-names>R</given-names></name><name><surname>Green</surname><given-names>G</given-names></name><name><surname>Dionne</surname><given-names>D</given-names></name><name><surname>Nguyen</surname><given-names>L</given-names></name><name><surname>Marshall</surname><given-names>JL</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Kaplan</surname><given-names>T</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Schwartz</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Disease-associated astrocytes in Alzheimer’s disease and aging</article-title><source>Nature Neuroscience</source><volume>23</volume><fpage>701</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1038/s41593-020-0624-8</pub-id><pub-id pub-id-type="pmid">32341542</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hinton</surname><given-names>GE</given-names></name></person-group><year iso-8601-date="2002">2002</year><chapter-title>Stochastic Neighbor Embedding</chapter-title><source>In Advances in Neural Information Processing Systems</source><publisher-name>NeurIPS Proceedings</publisher-name><fpage>833</fpage><lpage>840</lpage></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jongsma</surname><given-names>MLM</given-names></name><name><surname>de Waard</surname><given-names>AA</given-names></name><name><surname>Raaben</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Cabukusta</surname><given-names>B</given-names></name><name><surname>Platzer</surname><given-names>R</given-names></name><name><surname>Blomen</surname><given-names>VA</given-names></name><name><surname>Xagara</surname><given-names>A</given-names></name><name><surname>Verkerk</surname><given-names>T</given-names></name><name><surname>Bliss</surname><given-names>S</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Gerke</surname><given-names>C</given-names></name><name><surname>Janssen</surname><given-names>L</given-names></name><name><surname>Stickel</surname><given-names>E</given-names></name><name><surname>Holst</surname><given-names>S</given-names></name><name><surname>Plomp</surname><given-names>R</given-names></name><name><surname>Mulder</surname><given-names>A</given-names></name><name><surname>Ferrone</surname><given-names>S</given-names></name><name><surname>Claas</surname><given-names>FHJ</given-names></name><name><surname>Heemskerk</surname><given-names>MHM</given-names></name><name><surname>Griffioen</surname><given-names>M</given-names></name><name><surname>Halenius</surname><given-names>A</given-names></name><name><surname>Overkleeft</surname><given-names>H</given-names></name><name><surname>Huppa</surname><given-names>JB</given-names></name><name><surname>Wuhrer</surname><given-names>M</given-names></name><name><surname>Brummelkamp</surname><given-names>TR</given-names></name><name><surname>Neefjes</surname><given-names>J</given-names></name><name><surname>Spaapen</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The sppl3-defined glycosphingolipid repertoire orchestrates hla class i-mediated immune responses</article-title><source>Immunity</source><volume>54</volume><fpage>132</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.11.003</pub-id><pub-id pub-id-type="pmid">33271119</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanfer</surname><given-names>JN</given-names></name><name><surname>Stephens</surname><given-names>MC</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Legler</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>The Gaucher mouse</article-title><source>Progress in Clinical and Biological Research</source><volume>95</volume><fpage>627</fpage><lpage>644</lpage><pub-id pub-id-type="pmid">6812089</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlhofer</surname><given-names>FM</given-names></name><name><surname>Ribaudo</surname><given-names>RK</given-names></name><name><surname>Yokoyama</surname><given-names>WM</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells</article-title><source>Nature</source><volume>358</volume><fpage>66</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/358066a0</pub-id><pub-id pub-id-type="pmid">1614533</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalil</surname><given-names>M</given-names></name><name><surname>Pirpamer</surname><given-names>L</given-names></name><name><surname>Hofer</surname><given-names>E</given-names></name><name><surname>Voortman</surname><given-names>MM</given-names></name><name><surname>Barro</surname><given-names>C</given-names></name><name><surname>Leppert</surname><given-names>D</given-names></name><name><surname>Benkert</surname><given-names>P</given-names></name><name><surname>Ropele</surname><given-names>S</given-names></name><name><surname>Enzinger</surname><given-names>C</given-names></name><name><surname>Fazekas</surname><given-names>F</given-names></name><name><surname>Schmidt</surname><given-names>R</given-names></name><name><surname>Kuhle</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Serum neurofilament light levels in normal aging and their association with morphologic brain changes</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>812</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-14612-6</pub-id><pub-id pub-id-type="pmid">32041951</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>G</given-names></name><name><surname>Wegdam</surname><given-names>W</given-names></name><name><surname>Donker-Koopman</surname><given-names>W</given-names></name><name><surname>Ottenhoff</surname><given-names>R</given-names></name><name><surname>Gaspar</surname><given-names>P</given-names></name><name><surname>Verhoek</surname><given-names>M</given-names></name><name><surname>Nelson</surname><given-names>J</given-names></name><name><surname>Gabriel</surname><given-names>T</given-names></name><name><surname>Kallemeijn</surname><given-names>W</given-names></name><name><surname>Boot</surname><given-names>RG</given-names></name><name><surname>Laman</surname><given-names>JD</given-names></name><name><surname>Vissers</surname><given-names>JPC</given-names></name><name><surname>Cox</surname><given-names>T</given-names></name><name><surname>Pavlova</surname><given-names>E</given-names></name><name><surname>Moran</surname><given-names>MT</given-names></name><name><surname>Aerts</surname><given-names>JM</given-names></name><name><surname>van Eijk</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Elevation of glycoprotein nonmetastatic melanoma protein B in type 1 Gaucher disease patients and mouse models</article-title><source>FEBS Open Bio</source><volume>6</volume><fpage>902</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1002/2211-5463.12078</pub-id><pub-id pub-id-type="pmid">27642553</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JK</given-names></name><name><surname>Tansey</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Microglia isolation from adult mouse brain</article-title><source>Methods in Molecular Biology</source><volume>1041</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1007/978-1-62703-520-0_3</pub-id><pub-id pub-id-type="pmid">23813365</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeffler</surname><given-names>T</given-names></name><name><surname>Schilcher</surname><given-names>I</given-names></name><name><surname>Flunkert</surname><given-names>S</given-names></name><name><surname>Hutter-Paier</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Neurofilament-light chain as biomarker of neurodegenerative and rare diseases with high translational value</article-title><source>Frontiers in Neuroscience</source><volume>14</volume><elocation-id>579</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2020.00579</pub-id><pub-id pub-id-type="pmid">32595447</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahad</surname><given-names>D</given-names></name><name><surname>Callahan</surname><given-names>MK</given-names></name><name><surname>Williams</surname><given-names>KA</given-names></name><name><surname>Ubogu</surname><given-names>EE</given-names></name><name><surname>Kivisäkk</surname><given-names>P</given-names></name><name><surname>Tucky</surname><given-names>B</given-names></name><name><surname>Kidd</surname><given-names>G</given-names></name><name><surname>Kingsbury</surname><given-names>GA</given-names></name><name><surname>Chang</surname><given-names>A</given-names></name><name><surname>Fox</surname><given-names>RJ</given-names></name><name><surname>Mack</surname><given-names>M</given-names></name><name><surname>Sniderman</surname><given-names>MB</given-names></name><name><surname>Ravid</surname><given-names>R</given-names></name><name><surname>Staugaitis</surname><given-names>SM</given-names></name><name><surname>Stins</surname><given-names>MF</given-names></name><name><surname>Ransohoff</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis</article-title><source>Brain</source><volume>129</volume><fpage>212</fpage><lpage>223</lpage><pub-id pub-id-type="doi">10.1093/brain/awh655</pub-id><pub-id pub-id-type="pmid">16230319</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendiola</surname><given-names>AS</given-names></name><name><surname>Ryu</surname><given-names>JK</given-names></name><name><surname>Bardehle</surname><given-names>S</given-names></name><name><surname>Meyer-Franke</surname><given-names>A</given-names></name><name><surname>Ang</surname><given-names>KK-H</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Baeten</surname><given-names>KM</given-names></name><name><surname>Hanspers</surname><given-names>K</given-names></name><name><surname>Merlini</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><name><surname>Petersen</surname><given-names>MA</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>R</given-names></name><name><surname>Rafalski</surname><given-names>VA</given-names></name><name><surname>Meza-Acevedo</surname><given-names>R</given-names></name><name><surname>Tognatta</surname><given-names>R</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Pfaff</surname><given-names>SJ</given-names></name><name><surname>Machado</surname><given-names>MR</given-names></name><name><surname>Bedard</surname><given-names>C</given-names></name><name><surname>Rios Coronado</surname><given-names>PE</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Pleiss</surname><given-names>MA</given-names></name><name><surname>Green</surname><given-names>AJ</given-names></name><name><surname>Zamvil</surname><given-names>SS</given-names></name><name><surname>Pico</surname><given-names>AR</given-names></name><name><surname>Bruneau</surname><given-names>BG</given-names></name><name><surname>Arkin</surname><given-names>MR</given-names></name><name><surname>Akassoglou</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transcriptional profiling and therapeutic targeting of oxidative stress in neuroinflammation</article-title><source>Nature Immunology</source><volume>21</volume><fpage>513</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1038/s41590-020-0654-0</pub-id><pub-id pub-id-type="pmid">32284594</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Nottoli</surname><given-names>T</given-names></name><name><surname>McGrath</surname><given-names>J</given-names></name><name><surname>Jain</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Keutzer</surname><given-names>J</given-names></name><name><surname>Chuang</surname><given-names>WL</given-names></name><name><surname>Chuang</surname><given-names>WL</given-names></name><name><surname>Mehal</surname><given-names>WZ</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>A</given-names></name><name><surname>Mane</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Peng</surname><given-names>YZ</given-names></name><name><surname>Li</surname><given-names>JH</given-names></name><name><surname>Agrawal</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>LL</given-names></name><name><surname>Blair</surname><given-names>HC</given-names></name><name><surname>Robinson</surname><given-names>LJ</given-names></name><name><surname>Iqbal</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Zaidi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage</article-title><source>PNAS</source><volume>107</volume><fpage>19473</fpage><lpage>19478</lpage><pub-id pub-id-type="doi">10.1073/pnas.1003308107</pub-id><pub-id pub-id-type="pmid">20962279</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Chuang</surname><given-names>WL</given-names></name><name><surname>Yuen</surname><given-names>T</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Lu</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Keutzer</surname><given-names>J</given-names></name><name><surname>Stachnik</surname><given-names>A</given-names></name><name><surname>Mennone</surname><given-names>A</given-names></name><name><surname>Boyer</surname><given-names>JL</given-names></name><name><surname>Jain</surname><given-names>D</given-names></name><name><surname>Brady</surname><given-names>RO</given-names></name><name><surname>New</surname><given-names>MI</given-names></name><name><surname>Zaidi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease</article-title><source>PNAS</source><volume>111</volume><fpage>4934</fpage><lpage>4939</lpage><pub-id pub-id-type="doi">10.1073/pnas.1400768111</pub-id><pub-id pub-id-type="pmid">24639522</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Batista</surname><given-names>JL</given-names></name><name><surname>Andersson</surname><given-names>HC</given-names></name><name><surname>Balwani</surname><given-names>M</given-names></name><name><surname>Burrow</surname><given-names>TA</given-names></name><name><surname>Charrow</surname><given-names>J</given-names></name><name><surname>Kaplan</surname><given-names>P</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Kishnani</surname><given-names>PS</given-names></name><name><surname>Kolodny</surname><given-names>EH</given-names></name><name><surname>Rosenbloom</surname><given-names>B</given-names></name><name><surname>Scott</surname><given-names>CR</given-names></name><name><surname>Weinreb</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry</article-title><source>American Journal of Hematology</source><volume>92</volume><fpage>929</fpage><lpage>939</lpage><pub-id pub-id-type="doi">10.1002/ajh.24801</pub-id><pub-id pub-id-type="pmid">28569047</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Lukina</surname><given-names>E</given-names></name><name><surname>Ben Turkia</surname><given-names>H</given-names></name><name><surname>Shankar</surname><given-names>SP</given-names></name><name><surname>Baris</surname><given-names>H</given-names></name><name><surname>Ghosn</surname><given-names>M</given-names></name><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Packman</surname><given-names>S</given-names></name><name><surname>Pastores</surname><given-names>G</given-names></name><name><surname>Petakov</surname><given-names>M</given-names></name><name><surname>Assouline</surname><given-names>S</given-names></name><name><surname>Balwani</surname><given-names>M</given-names></name><name><surname>Danda</surname><given-names>S</given-names></name><name><surname>Hadjiev</surname><given-names>E</given-names></name><name><surname>Ortega</surname><given-names>A</given-names></name><name><surname>Gaemers</surname><given-names>SJM</given-names></name><name><surname>Tayag</surname><given-names>R</given-names></name><name><surname>Peterschmitt</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Outcomes after 18 months of eliglustat therapy in treatment-naïve adults with Gaucher disease type 1: The phase 3 ENGAGE trial</article-title><source>American Journal of Hematology</source><volume>92</volume><fpage>1170</fpage><lpage>1176</lpage><pub-id pub-id-type="doi">10.1002/ajh.24877</pub-id><pub-id pub-id-type="pmid">28762527</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murugesan</surname><given-names>V</given-names></name><name><surname>Chuang</surname><given-names>WL</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Lischuk</surname><given-names>A</given-names></name><name><surname>Kacena</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name><name><surname>Pastores</surname><given-names>GM</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Keutzer</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Mistry</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Glucosylsphingosine is a key biomarker of Gaucher disease</article-title><source>American Journal of Hematology</source><volume>91</volume><fpage>1082</fpage><lpage>1089</lpage><pub-id pub-id-type="doi">10.1002/ajh.24491</pub-id><pub-id pub-id-type="pmid">27441734</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagata</surname><given-names>M</given-names></name><name><surname>Izumi</surname><given-names>Y</given-names></name><name><surname>Ishikawa</surname><given-names>E</given-names></name><name><surname>Kiyotake</surname><given-names>R</given-names></name><name><surname>Doi</surname><given-names>R</given-names></name><name><surname>Iwai</surname><given-names>S</given-names></name><name><surname>Omahdi</surname><given-names>Z</given-names></name><name><surname>Yamaji</surname><given-names>T</given-names></name><name><surname>Miyamoto</surname><given-names>T</given-names></name><name><surname>Bamba</surname><given-names>T</given-names></name><name><surname>Yamasaki</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Intracellular metabolite β-glucosylceramide is an endogenous Mincle ligand possessing immunostimulatory activity</article-title><source>PNAS</source><volume>114</volume><fpage>E3285</fpage><lpage>E3294</lpage><pub-id pub-id-type="doi">10.1073/pnas.1618133114</pub-id><pub-id pub-id-type="pmid">28373578</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Boddupalli</surname><given-names>CS</given-names></name><name><surname>Verma</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>R</given-names></name><name><surname>Pastores</surname><given-names>GM</given-names></name><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Dhodapkar</surname><given-names>MV</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation</article-title><source>Blood</source><volume>125</volume><fpage>1256</fpage><lpage>1271</lpage><pub-id pub-id-type="doi">10.1182/blood-2014-09-600270</pub-id><pub-id pub-id-type="pmid">25499455</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nair</surname><given-names>S</given-names></name><name><surname>Branagan</surname><given-names>AR</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Boddupalli</surname><given-names>CS</given-names></name><name><surname>Mistry</surname><given-names>PK</given-names></name><name><surname>Dhodapkar</surname><given-names>MV</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Clonal immunoglobulin against lysolipids in the origin of myeloma</article-title><source>The New England Journal of Medicine</source><volume>374</volume><fpage>555</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1508808</pub-id><pub-id pub-id-type="pmid">26863356</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pandey</surname><given-names>MK</given-names></name><name><surname>Burrow</surname><given-names>TA</given-names></name><name><surname>Rani</surname><given-names>R</given-names></name><name><surname>Martin</surname><given-names>LJ</given-names></name><name><surname>Witte</surname><given-names>D</given-names></name><name><surname>Setchell</surname><given-names>KD</given-names></name><name><surname>Mckay</surname><given-names>MA</given-names></name><name><surname>Magnusen</surname><given-names>AF</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Liou</surname><given-names>B</given-names></name><name><surname>Köhl</surname><given-names>J</given-names></name><name><surname>Grabowski</surname><given-names>GA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Complement drives glucosylceramide accumulation and tissue inflammation in Gaucher disease</article-title><source>Nature</source><volume>543</volume><fpage>108</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1038/nature21368</pub-id><pub-id pub-id-type="pmid">28225753</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platt</surname><given-names>FM</given-names></name><name><surname>d’Azzo</surname><given-names>A</given-names></name><name><surname>Davidson</surname><given-names>BL</given-names></name><name><surname>Neufeld</surname><given-names>EF</given-names></name><name><surname>Tifft</surname><given-names>CJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Lysosomal storage diseases</article-title><source>Nature Reviews. Disease Primers</source><volume>4</volume><elocation-id>27</elocation-id><pub-id pub-id-type="doi">10.1038/s41572-018-0025-4</pub-id><pub-id pub-id-type="pmid">30275469</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satija</surname><given-names>R</given-names></name><name><surname>Farrell</surname><given-names>JA</given-names></name><name><surname>Gennert</surname><given-names>D</given-names></name><name><surname>Schier</surname><given-names>AF</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Spatial reconstruction of single-cell gene expression data</article-title><source>Nature Biotechnology</source><volume>33</volume><fpage>495</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1038/nbt.3192</pub-id><pub-id pub-id-type="pmid">25867923</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiffmann</surname><given-names>R</given-names></name><name><surname>Fitzgibbon</surname><given-names>EJ</given-names></name><name><surname>Harris</surname><given-names>C</given-names></name><name><surname>DeVile</surname><given-names>C</given-names></name><name><surname>Davies</surname><given-names>EH</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>van Schaik</surname><given-names>IN</given-names></name><name><surname>Benko</surname><given-names>W</given-names></name><name><surname>Timmons</surname><given-names>M</given-names></name><name><surname>Ries</surname><given-names>M</given-names></name><name><surname>Vellodi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Randomized, controlled trial of miglustat in Gaucher’s disease type 3</article-title><source>Annals of Neurology</source><volume>64</volume><fpage>514</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1002/ana.21491</pub-id><pub-id pub-id-type="pmid">19067373</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiffmann</surname><given-names>R</given-names></name><name><surname>Cox</surname><given-names>TM</given-names></name><name><surname>Ida</surname><given-names>H</given-names></name><name><surname>Mengel</surname><given-names>E</given-names></name><name><surname>Mistry</surname><given-names>P</given-names></name><name><surname>Crawford</surname><given-names>N</given-names></name><name><surname>Gaemers</surname><given-names>S</given-names></name><name><surname>Ji</surname><given-names>A</given-names></name><name><surname>Peterschmitt</surname><given-names>MJ</given-names></name><name><surname>Sharma</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Fischer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Venglustat combined with imiglucerase positively affects neurological features and brain connectivity in adults with Gaucher disease type 3</article-title><source>Molecular Genetics and Metabolism</source><volume>129</volume><fpage>S144</fpage><lpage>S145</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2019.11.382</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Serrano-Pozo</surname><given-names>A</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>APOE and Alzheimer’s disease: advances in genetics, pathophysiology, and therapeutic approaches</article-title><source>The Lancet. Neurology</source><volume>20</volume><fpage>68</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(20)30412-9</pub-id><pub-id pub-id-type="pmid">33340485</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shayman</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Eliglustat tartrate: Glucosylceramide synthase inhibitor treatment of type 1 gaucher disease</article-title><source>Drugs of the Future</source><volume>35</volume><fpage>613</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">22563139</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibuya</surname><given-names>Y</given-names></name><name><surname>Kumar</surname><given-names>KK</given-names></name><name><surname>Mader</surname><given-names>MM-D</given-names></name><name><surname>Yoo</surname><given-names>Y</given-names></name><name><surname>Ayala</surname><given-names>LA</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Mohr</surname><given-names>MA</given-names></name><name><surname>Neumayer</surname><given-names>G</given-names></name><name><surname>Kumar</surname><given-names>I</given-names></name><name><surname>Yamamoto</surname><given-names>R</given-names></name><name><surname>Marcoux</surname><given-names>P</given-names></name><name><surname>Liou</surname><given-names>B</given-names></name><name><surname>Bennett</surname><given-names>FC</given-names></name><name><surname>Nakauchi</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Heppner</surname><given-names>FL</given-names></name><name><surname>Wyss-Coray</surname><given-names>T</given-names></name><name><surname>Südhof</surname><given-names>TC</given-names></name><name><surname>Wernig</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Treatment of a genetic brain disease by CNS-wide microglia replacement</article-title><source>Science Translational Medicine</source><volume>14</volume><elocation-id>eabl9945</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abl9945</pub-id><pub-id pub-id-type="pmid">35294256</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiner</surname><given-names>T</given-names></name><name><surname>Mirelman</surname><given-names>A</given-names></name><name><surname>Rosenblum</surname><given-names>Y</given-names></name><name><surname>Kavé</surname><given-names>G</given-names></name><name><surname>Weisz</surname><given-names>MG</given-names></name><name><surname>Bar-Shira</surname><given-names>A</given-names></name><name><surname>Goldstein</surname><given-names>O</given-names></name><name><surname>Thaler</surname><given-names>A</given-names></name><name><surname>Gurevich</surname><given-names>T</given-names></name><name><surname>Orr-Urtreger</surname><given-names>A</given-names></name><name><surname>Giladi</surname><given-names>N</given-names></name><name><surname>Bregman</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The effect of gba mutations and apoe polymorphisms on dementia with lewy bodies in ashkenazi jews</article-title><source>Journal of Alzheimer’s Disease</source><volume>80</volume><fpage>1221</fpage><lpage>1229</lpage><pub-id pub-id-type="doi">10.3233/JAD-201295</pub-id><pub-id pub-id-type="pmid">33646158</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidransky</surname><given-names>E</given-names></name><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Aasly</surname><given-names>JO</given-names></name><name><surname>Aharon-Peretz</surname><given-names>J</given-names></name><name><surname>Annesi</surname><given-names>G</given-names></name><name><surname>Barbosa</surname><given-names>ER</given-names></name><name><surname>Bar-Shira</surname><given-names>A</given-names></name><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Bras</surname><given-names>J</given-names></name><name><surname>Brice</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>CM</given-names></name><name><surname>Clark</surname><given-names>LN</given-names></name><name><surname>Condroyer</surname><given-names>C</given-names></name><name><surname>Marco</surname><given-names>EVD</given-names></name><name><surname>Durr</surname><given-names>A</given-names></name><name><surname>Eblan</surname><given-names>MJ</given-names></name><name><surname>Fahn</surname><given-names>S</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><name><surname>Fung</surname><given-names>HC</given-names></name><name><surname>Gan-Or</surname><given-names>Z</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Gershoni-Baruch</surname><given-names>R</given-names></name><name><surname>Giladi</surname><given-names>N</given-names></name><name><surname>Griffith</surname><given-names>A</given-names></name><name><surname>Gurevich</surname><given-names>T</given-names></name><name><surname>Januario</surname><given-names>C</given-names></name><name><surname>Kropp</surname><given-names>P</given-names></name><name><surname>Lang</surname><given-names>AE</given-names></name><name><surname>Lee-Chen</surname><given-names>GJ</given-names></name><name><surname>Lesage</surname><given-names>S</given-names></name><name><surname>Marder</surname><given-names>K</given-names></name><name><surname>Mata</surname><given-names>IF</given-names></name><name><surname>Mirelman</surname><given-names>A</given-names></name><name><surname>Mitsui</surname><given-names>J</given-names></name><name><surname>Mizuta</surname><given-names>I</given-names></name><name><surname>Nicoletti</surname><given-names>G</given-names></name><name><surname>Oliveira</surname><given-names>C</given-names></name><name><surname>Ottman</surname><given-names>R</given-names></name><name><surname>Orr-Urtreger</surname><given-names>A</given-names></name><name><surname>Pereira</surname><given-names>LV</given-names></name><name><surname>Quattrone</surname><given-names>A</given-names></name><name><surname>Rogaeva</surname><given-names>E</given-names></name><name><surname>Rolfs</surname><given-names>A</given-names></name><name><surname>Rosenbaum</surname><given-names>H</given-names></name><name><surname>Rozenberg</surname><given-names>R</given-names></name><name><surname>Samii</surname><given-names>A</given-names></name><name><surname>Samaddar</surname><given-names>T</given-names></name><name><surname>Schulte</surname><given-names>C</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Singleton</surname><given-names>A</given-names></name><name><surname>Spitz</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>EK</given-names></name><name><surname>Tayebi</surname><given-names>N</given-names></name><name><surname>Toda</surname><given-names>T</given-names></name><name><surname>Troiano</surname><given-names>AR</given-names></name><name><surname>Tsuji</surname><given-names>S</given-names></name><name><surname>Wittstock</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease</article-title><source>The New England Journal of Medicine</source><volume>361</volume><fpage>1651</fpage><lpage>1661</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0901281</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidransky</surname><given-names>E</given-names></name><name><surname>Lopez</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The link between the GBA gene and parkinsonism</article-title><source>The Lancet. Neurology</source><volume>11</volume><fpage>986</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1016/S1474-4422(12)70190-4</pub-id><pub-id pub-id-type="pmid">23079555</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takizawa</surname><given-names>H</given-names></name><name><surname>Regoes</surname><given-names>RR</given-names></name><name><surname>Boddupalli</surname><given-names>CS</given-names></name><name><surname>Bonhoeffer</surname><given-names>S</given-names></name><name><surname>Manz</surname><given-names>MG</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Dynamic variation in cycling of hematopoietic stem cells in steady state and inflammation</article-title><source>The Journal of Experimental Medicine</source><volume>208</volume><fpage>273</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1084/jem.20101643</pub-id><pub-id pub-id-type="pmid">21300914</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vardi</surname><given-names>A</given-names></name><name><surname>Ben-Dor</surname><given-names>S</given-names></name><name><surname>Cho</surname><given-names>SM</given-names></name><name><surname>Kalinke</surname><given-names>U</given-names></name><name><surname>Spanier</surname><given-names>J</given-names></name><name><surname>Futerman</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mice defective in interferon signaling help distinguish between primary and secondary pathological pathways in a mouse model of neuronal forms of Gaucher disease</article-title><source>Journal of Neuroinflammation</source><volume>17</volume><elocation-id>265</elocation-id><pub-id pub-id-type="doi">10.1186/s12974-020-01934-x</pub-id><pub-id pub-id-type="pmid">32892753</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>BD</given-names></name><name><surname>Guillaume</surname><given-names>JL</given-names></name><name><surname>Lambiotte</surname><given-names>R</given-names></name><name><surname>Lefebvre</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Fast unfolding of communities in large networks</article-title><source>Journal of Statistical Mechanics</source><volume>10</volume><elocation-id>10008</elocation-id><pub-id pub-id-type="doi">10.1088/1742-5468/2008/10/P10008</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vitner</surname><given-names>EB</given-names></name><name><surname>Dekel</surname><given-names>H</given-names></name><name><surname>Zigdon</surname><given-names>H</given-names></name><name><surname>Shachar</surname><given-names>T</given-names></name><name><surname>Farfel-Becker</surname><given-names>T</given-names></name><name><surname>Eilam</surname><given-names>R</given-names></name><name><surname>Karlsson</surname><given-names>S</given-names></name><name><surname>Futerman</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Altered expression and distribution of cathepsins in neuronopathic forms of Gaucher disease and in other sphingolipidoses</article-title><source>Human Molecular Genetics</source><volume>19</volume><fpage>3583</fpage><lpage>3590</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddq273</pub-id><pub-id pub-id-type="pmid">20616152</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vitner</surname><given-names>EB</given-names></name><name><surname>Vardi</surname><given-names>A</given-names></name><name><surname>Cox</surname><given-names>TM</given-names></name><name><surname>Futerman</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Emerging therapeutic targets for Gaucher disease</article-title><source>Expert Opinion on Therapeutic Targets</source><volume>19</volume><fpage>321</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1517/14728222.2014.981530</pub-id><pub-id pub-id-type="pmid">25416676</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walzer</surname><given-names>T</given-names></name><name><surname>Chiossone</surname><given-names>L</given-names></name><name><surname>Chaix</surname><given-names>J</given-names></name><name><surname>Calver</surname><given-names>A</given-names></name><name><surname>Carozzo</surname><given-names>C</given-names></name><name><surname>Garrigue-Antar</surname><given-names>L</given-names></name><name><surname>Jacques</surname><given-names>Y</given-names></name><name><surname>Baratin</surname><given-names>M</given-names></name><name><surname>Tomasello</surname><given-names>E</given-names></name><name><surname>Vivier</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor</article-title><source>Nature Immunology</source><volume>8</volume><fpage>1337</fpage><lpage>1344</lpage><pub-id pub-id-type="doi">10.1038/ni1523</pub-id><pub-id pub-id-type="pmid">17965716</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Mustafa</surname><given-names>M</given-names></name><name><surname>Yuede</surname><given-names>CM</given-names></name><name><surname>Salazar</surname><given-names>SV</given-names></name><name><surname>Kong</surname><given-names>P</given-names></name><name><surname>Long</surname><given-names>H</given-names></name><name><surname>Ward</surname><given-names>M</given-names></name><name><surname>Siddiqui</surname><given-names>O</given-names></name><name><surname>Paul</surname><given-names>R</given-names></name><name><surname>Gilfillan</surname><given-names>S</given-names></name><name><surname>Ibrahim</surname><given-names>A</given-names></name><name><surname>Rhinn</surname><given-names>H</given-names></name><name><surname>Tassi</surname><given-names>I</given-names></name><name><surname>Rosenthal</surname><given-names>A</given-names></name><name><surname>Schwabe</surname><given-names>T</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer’s disease model</article-title><source>The Journal of Experimental Medicine</source><volume>217</volume><elocation-id>e20200785</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20200785</pub-id><pub-id pub-id-type="pmid">32579671</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weinhofer</surname><given-names>I</given-names></name><name><surname>Rommer</surname><given-names>P</given-names></name><name><surname>Zierfuss</surname><given-names>B</given-names></name><name><surname>Altmann</surname><given-names>P</given-names></name><name><surname>Foiani</surname><given-names>M</given-names></name><name><surname>Heslegrave</surname><given-names>A</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Gleiss</surname><given-names>A</given-names></name><name><surname>Musolino</surname><given-names>PL</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Forss-Petter</surname><given-names>S</given-names></name><name><surname>Berger</surname><given-names>T</given-names></name><name><surname>Eichler</surname><given-names>F</given-names></name><name><surname>Aubourg</surname><given-names>P</given-names></name><name><surname>Kohler</surname><given-names>W</given-names></name><name><surname>Berger</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>1816</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-22114-2</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>MW</given-names></name><name><surname>Shu</surname><given-names>L</given-names></name><name><surname>Hinkovska-Galcheva</surname><given-names>V</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Rajeswaran</surname><given-names>W</given-names></name><name><surname>Abe</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>T</given-names></name><name><surname>Luo</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wen</surname><given-names>B</given-names></name><name><surname>Liou</surname><given-names>B</given-names></name><name><surname>Fannin</surname><given-names>V</given-names></name><name><surname>Sun</surname><given-names>D</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Shayman</surname><given-names>JA</given-names></name><name><surname>Larsen</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Optimization of eliglustat-based glucosylceramide synthase inhibitors as substrate reduction therapy for gaucher disease type 3</article-title><source>ACS Chemical Neuroscience</source><volume>11</volume><fpage>3464</fpage><lpage>3473</lpage><pub-id pub-id-type="doi">10.1021/acschemneuro.0c00558</pub-id><pub-id pub-id-type="pmid">33035424</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>K</given-names></name><name><surname>Sidransky</surname><given-names>E</given-names></name><name><surname>Verma</surname><given-names>A</given-names></name><name><surname>Mixon</surname><given-names>T</given-names></name><name><surname>Sandberg</surname><given-names>GD</given-names></name><name><surname>Wakefield</surname><given-names>LK</given-names></name><name><surname>Morrison</surname><given-names>A</given-names></name><name><surname>Lwin</surname><given-names>A</given-names></name><name><surname>Colegial</surname><given-names>C</given-names></name><name><surname>Allman</surname><given-names>JM</given-names></name><name><surname>Schiffmann</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Neuropathology provides clues to the pathophysiology of Gaucher disease</article-title><source>Molecular Genetics and Metabolism</source><volume>82</volume><fpage>192</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.ymgme.2004.04.011</pub-id><pub-id pub-id-type="pmid">15234332</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yona</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name><name><surname>Wolf</surname><given-names>Y</given-names></name><name><surname>Mildner</surname><given-names>A</given-names></name><name><surname>Varol</surname><given-names>D</given-names></name><name><surname>Breker</surname><given-names>M</given-names></name><name><surname>Strauss-Ayali</surname><given-names>D</given-names></name><name><surname>Viukov</surname><given-names>S</given-names></name><name><surname>Guilliams</surname><given-names>M</given-names></name><name><surname>Misharin</surname><given-names>A</given-names></name><name><surname>Hume</surname><given-names>DA</given-names></name><name><surname>Perlman</surname><given-names>H</given-names></name><name><surname>Malissen</surname><given-names>B</given-names></name><name><surname>Zelzer</surname><given-names>E</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis</article-title><source>Immunity</source><volume>38</volume><fpage>79</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.12.001</pub-id><pub-id pub-id-type="pmid">23273845</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zigdon</surname><given-names>H</given-names></name><name><surname>Savidor</surname><given-names>A</given-names></name><name><surname>Levin</surname><given-names>Y</given-names></name><name><surname>Meshcheriakova</surname><given-names>A</given-names></name><name><surname>Schiffmann</surname><given-names>R</given-names></name><name><surname>Futerman</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Identification of a biomarker in cerebrospinal fluid for neuronopathic forms of Gaucher disease</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0120194</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0120194</pub-id><pub-id pub-id-type="pmid">25775479</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79830.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.05.13.491834" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.05.13.491834"/></front-stub><body><p>The pathophysiology of neuropathic Gaucher disease (nGD) is far from clear. This study not only provides mechanistic insights into the processes underpinning microglial activation and neuroinflammation but also implicates glycosylceramide in the pathogenesis of nGD through the use of a novel inhibitor. Overall, the landmark study substantially improves our understanding of nGD with significant therapeutic ramifications.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79830.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zaidi</surname><given-names>Mone</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04a9tmd77</institution-id><institution>Icahn School of Medicine at Mount Sinai</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.05.13.491834">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.05.13.491834v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Neuroinflammation in neuronopathic Gaucher disease: Role of microglia and NK cells&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by Mone Zaidi. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Line 142: Define MFs abbreviation.</p><p>2) Line 157: Sentence not clear, a connecting word seems to be missing.</p><p>3) Legend to Figure 1 lists a panel (H) that is not shown in the Figure.</p><p>4) Line 231: In the sentence….. we could not detect Pro IL-1ß induction in microglia of Gbaloxp/loxp Cx3cr1Cre/+ mice (Figure S5E)., the text refers to Figure S5D, not S5E. Correction is needed.</p><p>5) There is no further reference to Figure S5E in the text.</p><p>6) Revise the legend to Figure S5D and S5E to reflect what is shown in the figure.</p><p>7) Line 186. I suggest the authors comment on why restoration of Gba in neurons of nGD mice blocked attrition of microglia (Figure 2C).</p><p>8) Figure 4. Is there an explanation for why there is more infiltration of NK cells in nGD than in nGD Cx3cr1Cre/+ mice?</p><p>9) Figure 4I. The regimen of CBE administration should be included in the M and M.</p><p>10) Line 344/Figure 5F. Do the authors imply that Gba rescue in neurons prevents microglia activation? If so, they should elaborate on that.</p><p>11) Line 361. Remove &quot;restoring&quot; from the sentence.</p><p>12) Lines 368-371. The authors state that GZ161 increases the survival of nGD Cx3cr1Cre/+ mice by reducing the generation of GSLs in microglia. However, GZ161 acts not only on microglia but on other cells of the brain, including neurons. Therefore this sentence should be modified, as the beneficial effects of the GCS inhibitor may be due to its effects on more than one type of cell present in brain.</p><p>13) Figure 6D. Do the grey triangles represent nGD + GZ161? The Figure shows Gbalnl/lnl + GZ161. nGD + GZ161 should be used instead of Gbalnl/lnl + GZ161 for consistency and to avoid confusion.</p><p>14) Line 404. …. &quot;Intensity of LysoPC accumulation in brain microglia was significantly reduced by GZ-161 treatment&quot;. Are these results not shown?</p><p>15) Figure 8A. The authors should comment on the low levels of Nf-L in sera from mice with gba-rescued neurons, as the presence of gba in neurons seems to offset the deleterious effects of its absence in microglia and other tissues. Was GZ161 also tested in nGD NesCre/+ mice?</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>This study by Boddupalli et al., was well designed and conducted, the results were reasonably interpreted, and the manuscript was clearly written with logical inputs.</p><p>It would further gain the significance of this study by performing brain region or tissue-specific manipulations of the Gba signaling at single-cell resolution, instead of constitutive manipulations.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>In this manuscript, Boddupalli et al., did a careful analysis of the metabolic and molecular alterations caused by Gba deficiency in microglia, neurons, astrocytes, NK cells, macrophages, and other immune cells infiltrating the affected brain. The authors used a number of relevant animal models of neuronopathic Gaucher disease (nGD) that included Gba-null mice with restored Gba expression in either microglia or neurons, and mice in which Gba was deleted only in microglia. These models recapitulated early as well as late-onset nGD. Using single-cell analysis to define alterations in the different cell types present in the brains of Gba mutant mice, the authors clearly demonstrated deregulation of important neuroinflammatory networks at a single cell resolution level. Targeted rescue of Gba in microglia and in neurons of nGD mice reversed the buildup of GSLs with reversal of neuroinflammation and improved survival. The authors further showed that microglia activation was central to neuroinflammation in nGD. The work also identified early biomarkers to follow disease progression and response to treatment, which were validated using sera from patients with neuronopathic GD3 mutations, and in GD1 patients harboring mild mutations. The new markers identified included Nf-L and ApoE, whose levels in serum correlated with those of GluSph, a widely accepted marker of GD. Nf-L was elevated 2,000-fold in nGD mice, and there were also substantial elevations in adult GD1 patients compared to control adults. The authors also found significant differences in these disease markers between young and older GD1 patients. Nf-L and ApoE levels in the mutant mice and nGD patients were significantly reduced by brain-penetrant GluCer synthase inhibitors, further implicating elevated GSLs in the pathogenesis of Gba-associated neurodegeneration, and validating substrate reduction as a useful therapy. Another potential biomarker uncovered in these studies is LysoPC 16:1.</p><p>These results of this ground-breaking study are critically important for therapeutic development, as there is an unmet need to identify GD patients and GD carriers at risk for PD/LBD. In sum, the results presented are of great clinical significance, and I would recommend publication without delay.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79830.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Line 142: Define MFs abbreviation.</p></disp-quote><p>The abbreviation has been defined in the revised manuscript. See line 384:</p><p>CCR2<sup>+</sup> macrophages (MFs) defined as CD11b<sup>hi</sup> CD45<sup>+</sup>CCR2<sup>+</sup> CD64<sup>+</sup> TIMD4<sup>-</sup> population</p><disp-quote content-type="editor-comment"><p>2) Line 157: Sentence not clear, a connecting word seems to be missing.</p></disp-quote><p>The sentence has been modified please see line 398 in revised manuscript: For de novo characterization of the brain immune cell microenvironment, sorted CD45<sup>+</sup> cells from nGD and control brains were analyzed by scRNA-seq. Dimensionality reduction using t-distributed stochastic neighbor embedding (t-SNE) analysis revealed 15 distinct cellular clusters of CD45<sup>+</sup> cells (numbered 0-14) (Figure 1C). We assigned these clusters to individual immune subsets based on the expression of known marker genes (Figure 1C and figure supplement 1D and E).</p><disp-quote content-type="editor-comment"><p>3) Legend to Figure 1 lists a panel (H) that is not shown in the Figure.</p></disp-quote><p>Legend has been corrected and legend for panel H has been removed. Please see Line # 882.</p><disp-quote content-type="editor-comment"><p>4) Line 231: In the sentence….. we could not detect Pro IL-1ß induction in microglia of Gbaloxp/loxp Cx3cr1Cre/+ mice (Figure S5E)., the text refers to Figure S5D, not S5E. Correction is needed.</p></disp-quote><p>Figure panel as well as Figure3—figure supplement 1 legend has been changed to match the corresponding text. Please see line # 1078-1081 in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>5) There is no further reference to Figure S5E in the text.</p></disp-quote><p>Figure panel as well as Figure3—figure supplement 1 legend has been changed to match the corresponding text. Please see line # 1078-1081 in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>6) Revise the legend to Figure S5D and S5E to reflect what is shown in the figure.</p></disp-quote><p>Figure panel as well as Figure3—figure supplement 1 legend has been changed to match the corresponding text. Please see line # 1078-1081 in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>7) Line 186. I suggest the authors comment on why restoration of Gba in neurons of nGD mice blocked attrition of microglia (Figure 2C).</p></disp-quote><p>As pointed by the reviewer, restoration of Gba in neuronal compartment has significant effect on brain microglial maintenance. Please see lines 441-455 in revised manuscript addressing the reviewers comment:</p><p>“We depict this data, as fold elevation compared to wild type mice brains, of various glucosylceramides in nGD and after <italic>Gba</italic> rescue in microglia and neurons in Figure 2—figure supplement 2A which provides insight on relative contributions of microglia and neurons in the accumulation of the lipids in nGD. First, in <italic>Gba</italic> deficiency, the microglia display impressive capacity to process accumulating glucosylceramides and second that the major source of accumulating glucosylceramides in nGD appears to be the neuronal compartment. This is illustrated, by the observation that compared to wild type mice brains, in nGD mice, there is 200-fold elevation of brain C16-glucosylceramide, which falls to 5-fold elevation after microglia rescue and to 2.4-fold after neuronal rescue of <italic>Gba</italic>. Similar gradations are seen for brain GlcSph accumulation: 200-fold vs 20-fold vs 7-fold, respectively. Together, these observations suggest that reduced sphingolipid turnover observed in nGD <italic>Nes</italic><sup>Cre/+</sup> mice may exert a positive effect on overall microglial maintenance regardless of microglia cell intrinsic <italic>Gba</italic> deficiency. It seems likely, that diverse inflammatory responses triggered by sphingolipid induced neuronal damage observed in nGD and nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> brains could directly impact microglial maintenance and cell death.”</p><disp-quote content-type="editor-comment"><p>8) Figure 4. Is there an explanation for why there is more infiltration of NK cells in nGD than in nGD Cx3cr1Cre/+ mice?</p></disp-quote><p>Higher percentages of NK cell infiltration were observed in nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice brain as compared to nGD mice brain. It should be noted that there is increased attrition/death of microglia in nGD mice as compared to nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice. Taking these observations into consideration, we surmise that inflammatory cytokines and chemokines secreted by activated microglia which are present in higher proportion in nGD <italic>Cx3cr1</italic><sup>Cre/+</sup> mice induce robust NK cell infiltration into brains than seen in nGD mice. See lines 530-535.</p><disp-quote content-type="editor-comment"><p>9) Figure 4I. The regimen of CBE administration should be included in the M and M.</p></disp-quote><p>Regimen for CBE and GZ161 administration has been included in the M and M. Please see lines 154-159.</p><disp-quote content-type="editor-comment"><p>10) Line 344/Figure 5F. Do the authors imply that Gba rescue in neurons prevents microglia activation? If so, they should elaborate on that.</p></disp-quote><p>We thank the Reviewer for this comment. We have elaborated on this comment in our response #7 above.</p><p>Microglial activation was much less in nGD <italic>Nes</italic> <sup>Cre/+</sup> mice compared to nGD <italic>Cx3cr1</italic> <sup>Cre/+</sup> and nGD, we attribute this higher microglial activation phenomenon to abberant brain sphingolipid turnover seen in both nGD <italic>Cx3cr1</italic> <sup>Cre/+</sup> and nGD mice as compared to nGD <italic>Nes</italic> <sup>Cre/+</sup> mice.</p><disp-quote content-type="editor-comment"><p>11) Line 361. Remove &quot;restoring&quot; from the sentence.</p></disp-quote><p>The sentence has been corrected.</p><disp-quote content-type="editor-comment"><p>12) Lines 368-371. The authors state that GZ161 increases the survival of nGD Cx3cr1Cre/+ mice by reducing the generation of GSLs in microglia. However, GZ161 acts not only on microglia but on other cells of the brain, including neurons. Therefore this sentence should be modified, as the beneficial effects of the GCS inhibitor may be due to its effects on more than one type of cell present in brain.</p></disp-quote><p>The sentence has been modified according to the reviewer’s suggestion. Please see lines 638-642.</p><disp-quote content-type="editor-comment"><p>13) Figure 6D. Do the grey triangles represent nGD + GZ161? The Figure shows Gbalnl/lnl + GZ161. nGD + GZ161 should be used instead of Gbalnl/lnl + GZ161 for consistency and to avoid confusion.</p></disp-quote><p>Grey triangles do represent nGD + GZ161 and Figure 6D has been modified to reflect the same.</p><disp-quote content-type="editor-comment"><p>14) Line 404. …. &quot;Intensity of LysoPC accumulation in brain microglia was significantly reduced by GZ-161 treatment&quot;. Are these results not shown?</p></disp-quote><p>Yes, the data is shown in Figure 8G. The sentence has also been moved to line 731 in the revised manuscript.</p><disp-quote content-type="editor-comment"><p>15) Figure 8A. The authors should comment on the low levels of Nf-L in sera from mice with gba-rescued neurons, as the presence of gba in neurons seems to offset the deleterious effects of its absence in microglia and other tissues. Was GZ161 also tested in nGD NesCre/+ mice?</p></disp-quote><p>As reviewers rightly pointed out the selective knockout of <italic>gba</italic> from neurons using a nestin-cre system does not cause overt microglial attrition or inflammation, nevertheless as shown in (Figure 5—figure supplement 1D), nGD Nes <sup>Cre/+</sup> mice show decreased expression of homeostatic microglia markers as compared to littermate wild type control. It is therefore likely that low-grade microglial dyshomeostasis can lead to increase in low levels of Nf-L in sera of nGD Nes <sup>Cre/+</sup> mice. In addition to this we believe that absence of Gba function in multiple cell types of the brain could have caused low levels of Nf-L induction in nGD Nes <sup>Cre/+</sup> mice.</p><p>Regarding reviewers question whether we tested GZ161 in nGD Nes <sup>Cre/+</sup> mice, we did not test GZ161 in nGD NesCre/+ mice. We thank the Reviewer for this comment and plan to do this in future experiments.</p></body></sub-article></article>